The QualityStocks Daily Monday, September 20th, 2021

Today's Top 3 Investment Newsletters

MarketClub Analysis(CRVS) $5.3200 +135.40%

QualityStocks(SQZZF) $2.4500 +70.14%

The Street(FORG) $47.1500 +29.18%

The QualityStocks Daily Stock List

Theravance Biopharma (TBPH)

MarketBeat, InvestorPlace, The Online Investor, Kiplinger Today, Trades Of The Day, Marketbeat.com, Daily Trade Alert, Zacks, Wyatt Investment Research, StreetInsider, StockMarketWatch, Investiv, Investing Daily, Darwin Investing Network and BUYINS.NET reported earlier on Theravance Biopharma (TBPH), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Theravance Biopharma Inc. (NASDAQ: TBPH) (FRA: 0TB) is a biopharmaceutical firm that is focused on discovering, developing and commercializing organ-selective medications.

The firm has its headquarters in George Town, the Cayman Islands and was incorporated in July 2013. It operates as part of the pharmaceutical and medicine manufacturing industry, under the health care sector. The firm has four companies in its corporate family and serves consumers in the U.S. as well as in Asia and Europe.

The company is party to licensing and collaboration agreements with Takeda Pharmaceutical Company Ltd, Alfasigma S.p.A, Janssen Biotech Inc. and Pfizer Inc.

The enterprise’s pipeline comprises of a nebulized muscarinic antagonist dubbed Yupelri, which has been developed to treat chronic obstructive pulmonary disease. It also provides a selective 5-HT4 agonist indicated for the treatment of gastrointestinal motility disorders; a pan-janus kinase inhibitor dubbed Izencitinib, which is currently in a phase 2b/3 clinical trial evaluating its effectiveness in treating ulcerative colitis, myelofibrosis and rheumatoid arthritis, as well as various inflammatory intestinal diseases which include Crohn’s disease and ulcerative colitis. In addition to this, it also provides Trelegy, also indicated for the treatment of chronic obstructive pulmonary disease; a gut-selective JAK3inhibitor known as TD-5202, which is in a phase 1 clinical study testing its effectiveness in treating inflammatory intestinal diseases; and an investigational reuptake inhibitor known as Ampreloxetine, which has concluded its phase 3 study and is indicated for the treatment for neurogenic orthostatic hypotension.

The company is focused on leveraging its expertise in developing respiratory therapeutics in an effort to maximize shareholder value. This move is bound to bring in more investors into the company and boost its growth.

Theravance Biopharma (TBPH), closed Monday’s trading session at $6.88, off by 3.2349%, on 848,188 volume. The average volume for the last 3 months is 848,188 and the stock's 52-week low/high is $6.0999999/$22.7399997.

Ampio Pharmaceuticals (AMPE)

Profitable Trader Authority, StockMarketWatch, Ceocast News, BUYINS.NET, StreetInsider, MarketClub Analysis, Dynamic Wealth Report, The Street, MarketBeat, Hit and Run Candle Sticks, Rick Saddler, OTCtipReporter, Street Insider, PennyStockScholar, BestOtc, CRWEWallStreet, CRWEPicks, CRWEFinance, DrStockPick, Real Pennies, TradersPro, PennyToBuck, PennyTrader Publisher, PennyOmega, StockHotTips, TraderPower, CoolPennyStocks, The Online Investor, Stocks That Move, SmarTrend Newsletters, PennyStockCrowd, Greenbackers, INO.com Market Report, QualityStocks, MissionIR, Penny Stock Rumble, Wealthpire Inc. and Schaeffer's reported earlier on Ampio Pharmaceuticals (AMPE), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Ampio Pharmaceuticals Inc. (NYSE American: AMPE) (FRA: APH) is a biopharmaceutical firm that is engaged in developing new immunology-based therapies for treating common inflammatory conditions for which there are limited treatment options.

The firm has built a robust portfolio of issued patents and pending patent applications on its products. It also has strong relationships with specialized product and service providers, regional hospitals, academic medical centers and clinicians, which is central to its successful clinical development programs. It has sponsored clinical, basic and translational research projects which are aimed at particular disease mechanisms. The firm has its headquarters in Englewood, California and was incorporated in April 2020 by David Bar-Or. It serves consumers in the United States.

The enterprise’s product pipeline is made up of new molecular entities and new uses for already approved drugs developed for important therapeutic areas which include central nervous system ailments, sexual dysfunction, inflammation, kidney disease, eye disease and metabolic diseases. Its products include an intra-articular injection treatment dubbed Ampion, which contains small molecules and cyclized peptides derived from blood which targets various pathways affected by inflammatory ailments. The formulation is indicated for the treatment of severe osteoarthritis of the knee, as well as an inhaled treatment for coronavirus-induced respiratory distress and an IV treatment for the coronavirus disease. The enterprise is currently advancing the formulation’s clinical trials in the U.S.

The company’s Ampion candidate is being considered for emergency use authorization in the treatment of the coronavirus disease. Its approval would not only bring in more investors into the company but also benefit patients with this indication.

Ampio Pharmaceuticals (AMPE), closed Monday’s trading session at $1.64, off by 8.8889%, on 1,811,417 volume. The average volume for the last 3 months is 1.804M and the stock's 52-week low/high is $0.720799982/$2.98000001.

Avalo Therapeutics (AVTX)

We reported earlier on Avalo Therapeutics (AVTX), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Avalo Therapeutics Inc. (NASDAQ: AVTX) (FRA: C6K0) is a clinical stage medicine firm that is focused on discovering, developing and commercializing therapeutics for patients with unmet clinical needs in rare genetic, immune-oncology and immunology illnesses.

The firm has its headquarters in Rockville, Maryland and was incorporated in 2011, on January 31st by Solomon H. Snyder, Barbara S. Slusher, Isaac Blech and Blake M. Paterson. Prior to its name change in August 2021, the firm was known as Cerecor Inc. It operates as part of the scientific research and development services industry and serves consumers around the world.

The company uses a precision medicine approach to develop and commercialize highly targeted therapeutics. It operates a bioassay facility in Germantown.

The enterprise’s product pipeline is made up of an anti-light mAb dubbed AVTX-002, which targets immune-inflammatory ailments like moderate-to-severe inflammatory bowel disease and acute respiratory distress syndrome. It also offers an anti-IL-18 mAb, which targets immune-inflammatory and immune-oncology illnesses like Still’s disease and multiple myeloma. Still’s disease is a disorder that’s characterized by arthritis, a rash, high spiking fevers and inflammation. In addition to this, the enterprise also develops AVTX-801, AVTX-802 and AVTX-803, which are therapeutic monosaccharide therapy doses indicated for congenital disorders of glycosylation; and a dual mTORc1/c2 inhibitor dubbed AVTX-006, which targets lymphatic malformations.

The firm is focused on addressing the significant unmet medical need for patients and advancing its programs, having recently expanded its AVTX-002 program. Meeting these needs will not only extend the firm’s consumer reach but also encourage more investments into the firm, which will be good for its growth.

Avalo Therapeutics (AVTX), closed Monday’s trading session at $2.39, off by 5.9055%, on 912,307 volume. The average volume for the last 3 months is 912,307 and the stock's 52-week low/high is $1.98000001/$4.50.

ChromaDex Corp. (CDXC)

RedChip, QualityStocks, SmallCap Network, Wall Street Resources, BUYINS.NET, TraderPower, MarketBeat, StockMarketWatch, SmallCapVoice, FeedBlitz, Greenbackers, MarketClub Analysis, InvestorPlace, Marketbeat.com, Michael Stone, PennyStockLocks.com, Growing Stocks Reports, ResearchOTC, Stock Rocket Report, StockOodles, StockRockandRoll, TradersPro, Investor Update, DreamTeamNetwork, Daily Stock Motion, FreeRealTime, OTC Markets Group, Penny Pick Insider, Penny Stocks VIP, Real Pennies, Red Chip, Research Driven Investor, SECFilings.com News, Stock News Now, Stock Traders Chat, Trades Of The Day and PennyStocks24 reported earlier on ChromaDex Corp. (CDXC), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

ChromaDex Corp. (NASDAQ: CDXC) (FRA: OCD1) is an integrated nutraceutical firm that is engaged in the acquisition, development and commercialization of various ingredient technologies.

The firm has its headquarters in Los Angeles, California and was incorporated in 1999 by Frank L. Jaksch Jr. and Mark S. Germain. It serves consumers in the United States. The firm’s subsidiaries include Spherix Consulting Inc., ChromaDex Analytics Inc. and ChromaDex Inc.

The company operates through the Analytical reference standards and services, Ingredients and Consumer products segments. The analytical segment is involved in the supply of phytochemical reference standards and other R&D services while the ingredients segment is involved in the supply of ingredients as raw materials to consumer product manufacturers. On the other hand, the products segment is engaged in the provision of finished dietary supplement products which contain the company’s proprietary ingredients, directly to distributors and consumers.

The enterprise conducts research on NAD+ (nicotinamide adenine dinucleotide) and commercializes it as the flagship NIAGEN ingredient. NIAGEN is an active ingredient used in the enterprise’s consumer products under the Tru Niagen name. It also provides a Braun-type lipoprotein dubbed Immulina, which has been designed to support human immune function. Immulina includes active compounds and spirulina extracts. In addition to this, the enterprise provides reference standards and services that can be used to carry out quality control of consumer products and raw materials in pharmaceutical industries, life sciences, food and beverages, cosmetics and dietary supplements.

The company recently announced its latest financial results, which show strong growth delivery and that the company achieved record sales. Its CEO noted that the company was now focused on its long-term goals, noting that its prospects looked stronger than ever.

ChromaDex Corp. (CDXC), closed Monday’s trading session at $6.5, off by 3.9882%, on 543,706 volume. The average volume for the last 3 months is 497,029 and the stock's 52-week low/high is $3.81999993/$23.6599998.

Lineage Cell Therapeutics (LCTX)

BUYINS.NET, StockMarketWatch, TradersPro, Wealth Insider Alert, StreetInsider and MarketBeat reported earlier on Lineage Cell Therapeutics (LCTX), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Lineage Cell Therapeutics Inc. (NYSE American: LCTX) (FRA: BT3) is a clinical-stage biotechnology firm that is engaged in the development and commercialization of treatments for degenerative ailments.

The firm has its headquarters in Carlsbad, California and was incorporated in 1990, on November 30th by Harold D. Waitz, Paul E. Segall, Hal Sternberg and Judith Segall. Prior to its name change in August 2019, the firm was known as BioTime Inc. It serves patients across the globe.

The company is party to a collaboration with Orbit Biomedical Ltd. Its programs are based off of two core proprietary technology platforms, namely cell and drug delivery and cell replacement. The drug delivery programs are based on its HyStem cell and drug delivery matrix technology, while its cell replacement platform creates new tissues and cells with its progenitor and pluripotent cell technologies. The majority of the company’s revenue is generated from the United States.

The enterprise’s product pipeline includes an epithelium cell replacement therapy dubbed OpRegen which is indicated for the treatment of dry age-related macular degeneration and is currently undergoing a phase 2a clinical trial. It also offers an allogeneic cancer immunotherapy known as VAC2, which is currently in a phase 1 clinical trial evaluating its effectiveness in treating non-small cell lung cancer; and an oligodendrocyte progenitor cell therapy dubbed OPC1, which is undergoing a phase 1/2a clinical trial and has been developed to treat acute spinal cord injuries.

The firm reported their 2021 second quarter operating and financial results, with its CEO noting that the firm was focused on improving outcomes for individuals with degenerative ailments. The success of their formulations will have a positive influence on its growth as well as investments into the firm.

Lineage Cell Therapeutics (LCTX), closed Monday’s trading session at $2.35, off by 7.8431%, on 1,574,413 volume. The average volume for the last 3 months is 1.523M and the stock's 52-week low/high is $0.860000014/$3.1315999.

Zivo Bioscience (ZIVO)

QualityStocks, Ceocast News, RedChip and MarketBeat reported earlier on Zivo Bioscience (ZIVO), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Zivo Bioscience Inc. (NASDAQ: ZIVO) is a research and development firm that is focused on studying, developing and commercializing natural bioactive molecules and nutritional compounds extracted from its algae cultures, to human, animal and dietary medical food and supplement manufacturers.

The firm has its headquarters in Keego Harbor, Michigan and was incorporated in 1983, on March 28th by Howard R. Baer. Prior to its name change in October 2014, the firm was known as Health Enhancements Products Inc. It operates in the healthcare sector, under the biotech and pharma sub-industry and serves consumers across the globe.

The company is dedicated to discovering cost-effective and innovative technologies and techniques that help the highest number of individuals to access an extensive range of applications and products to serve their health and nutrition needs or the needs of the animals in their care. Zivo Bioscience strives to fully harness the benefits of its natural bioactive and nutritive products, make them readily available and affordable in a convenient and useful form.

The enterprise’s product pipeline comprises of a human dietary supplement dubbed ZIVO, which acts as a livestock feed additive, animal supplement, source of non-animal nutrition and enhances productivity as well as overall health. Its other product categories are functional food ingredients, human applications and animal applications. The enterprise also develops tests which enable individuals to identify future health risks and optimize their health.

Coccidiosis is among the biggest health concerns in the poultry industry. The firm has developed a drug candidate which boosts immune response and combats various infective pathogens in poultry. The formulation has undergone 2 separate studies and has been found to be effective. The use of the drug candidate will allow poultry producers to save money by improving productivity and feed conversion. This will make the firm even more attractive to investors.

Zivo Bioscience (ZIVO), closed Monday’s trading session at $4.66, up 66.4286%, on 120,563,723 volume. The average volume for the last 3 months is 120.564M and the stock's 52-week low/high is $2.72000002/$14.3999996.

All For One Media Corp. (AFOM)

Small Cap Firm, QualityStocks, Penny Stock Prodigy, The FrontPageStocks, DSR News, InvestorSoup, Jet-Life Penny Stocks, Penny Stock Craze, Penny Stock Finder, Penny Stock Hub, Beacon Equity Research, Penny Stocks Finder, Winston Small Cap, PHUB News, ProTrader, Stock Preacher, SuperStockTips and Penny Stock Titans reported earlier on All For One Media Corp. (AFOM), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

All For One Media Corp. is a tween marketing company listed on the OTC Markets’ OTCQB. Named “Generation I” for "Internet," this generation's tweens represent the first demographic to have had only known life with the Internet and social media. Essentially, All For One Media is a marketing brand changing the mindset of tweens that bullying is unacceptable. All For One Media has its head office in Mount Kisco, New York.

The Company is working to make the transition from a development stage corporation creating and acquiring media assets to a content provider launching many initiatives marketed to its core tween demographic. Its goal is to capitalize on a broad variety of potential revenue streams.

All For One Media, through entertainment, is working to deliver a message that will resonate with kids to impact the epidemic of bullying and cyber-bullying. In addition, it is working to help individuals who have been affected by bullying to deal with it in a positive and constructive manner.

All For One Media has produced Drama Drama (f/k/a "Crazy For the Boys"). Drama Drama is a full length coming of age musical dramedy. It features Groovy Tuesday music and choreography. This film tells the story of five high school girls from five very different cliques who must work together to run their school’s anti-bullying organization. The film features original pop songs pertaining to peer pressure, unrequited love, and teen angst. The expectation is that Drama Drama will generate revenues from numerous sources.

The Company has completed production of Drama Drama. It has started to screen the movie for buyers. Moreover, it engaged William Morris/Endeavor Content (WME) as the exclusive sales agent for the film. WME represents artists across all media platforms, particularly movies, television, music, theatre, digital and publishing.

All for One Media is making plans to commence group activities for the launch of the band "Drama Drama" concurrent to the release of the movie. The release of a full-length film used to promote the launch of a pop group is an industry first. The Company has also started negotiations with a number of major record labels for distribution of the film soundtrack.

All For One Media Corp. (AFOM), closed Monday’s trading session at $0.0008, up 33.3333%, on 166,902,753 volume. The average volume for the last 3 months is 166.903M and the stock's 52-week low/high is $0.000000999/$0.0052.

Bonanza Goldfields (BONZ)

QualityStocks, HyperGrowthStock, AheadoftheBulls.com, OTC Picks, Pennybuster, BestPicksEver, Stockpalooza, StockEgg, Bull in Advantage, CoolPennyStocks, HotOTC, BullRally, Greenbackers, MadPennyStocks, PennyInvest, PennyTrader Publisher, StockRich, Stock Traders Chat, PennyStockVille, Stock Marketing Inc., BreakthroughStocks Team, Stock Rich, SteroidStocks, Penny Invest, ShamrockStocks, Topgun stockpicks, MicrocapVoice, OTC Advisors, Otcstockexchange, OTCtipReporter, PennyStockScholar, PennyStocks24 and SmallCapVoice reported earlier on Bonanza Goldfields (BONZ), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Bonanza Goldfields Corporation (OTC: BONZ) is a mining and mineral exploration stage firm that is focused on exploring and acquiring rare earth elements and gold mineral properties in North America.

The firm has its headquarters in Las Vegas, Nevada and was incorporated in 2008, on March 6th. It provides its services in Arizona and Nevada and mainly explores for zinc, lead, silver and gold. The firm is yet to generate any revenue and its mineral properties include the Chloride Mining District and Tom Reed Tr. of Arizona and the Comstock Mining Districts of Nevada.

The enterprise’s flagship property is the Montezuma Stonewall, which is made up of patented mining claims of 60 acres of land found in the south of Goldfield, Nevada. It owns 2 sets of mineral properties in Arizona, the first being the Hull land and the second, federal mining claims on Bureau of Land Management land. Its project is made of 38 lode claims, which cover 455 acres of private and patented property claims. Both projects contain mineralized and alluvial quartz deposits and some rare earth elements. The company also has a net smelter royalty in production from the Thunder Mountain gold project, which is found between Round and Tonopah Mountain, located in Nevada.

The company recently acquired the Thunder Mountain project as part of an agreement with other related parties. This move will not only allow it to grow the extent of their operations but increase their revenues, which will be good for its growth.

Bonanza Goldfields (BONZ), closed Monday’s trading session at $0.0136, up 126.6667%, on 221,972,384 volume. The average volume for the last 3 months is 221.972M and the stock's 52-week low/high is $0.001799999/$0.035999998.

QS Energy, Inc. (QSEP)

QualityStocks, MarketBeat, RedChip, TopPennyStockMovers and PoliticsAndMyPortfolio reported earlier on QS Energy, Inc. (QSEP), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Established in 1998, QS Energy, Inc. is  a developer of integrated technology solutions for the energy industry. It develops and commercializes energy efficiency technologies that help in meeting rising global energy demands, improving the economics of oil extraction and transport, and lessening greenhouse gas emissions. The Company’s Intellectual Property  (IP) portfolio includes 48 domestic and worldwide patents and patents pending. These have undergone development in combination with, and exclusively licensed from, Temple University. OTCQB-listed, QS Energy is based in Tomball, Texas.

QS Energy’s AOT™ (Applied Oil Technology) is a group of commercial crude oil pipeline flow assurance products designed to undergo installation at pipeline pump stations in the upstream, gathering, and midstream sectors. AOT™ is an integrated system. It improves vital operational efficiencies for pipeline operators worldwide. The Company has its new strategic plan. The core mission of this plan is to expedite market adoption of its AOT™  technology.

AOT™ is an industrial hardware system and is completely fabricated in the U.S. AOT™  lowers the viscosity of unrefined oil utilizing low wattage electrical fields (electrorheology) to improve flow while in transit through pipelines. AOT™ technology delivers performance that can be measured in each of the areas of importance in the movement hydrocarbon stream - from reservoir to the point of sale.

QS Energy’s  AOT™ stand-alone or supplemental pipeline solutions increase flow rates. The Company’s solutions also reduce power consumption; optimize flow assurance; enhance pipeline integrity; and prevent bottlenecks. QS Energy is now positioned to complete its development from research and development (R&D) to commercialization.

QS Energy, Inc. (QSEP), closed Monday’s trading session at $0.038, up 32.1739%, on 103,300 volume. The average volume for the last 3 months is 103,300 and the stock's 52-week low/high is $0.009999999/$0.079999998.

Hammer Fiber Optic Investments Ltd. (HMMR)

Tip.us, QualityStocks, TraderPower, NetworkNewsWire, MissionIR, StocksToBuyNow, SeriousTraders, RedChip, PoliticsAndMyPortfolio and Wall Street Mover reported earlier on Hammer Fiber Optic Investments Ltd. (HMMR), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Hammer Fiber serves Residential and SME customers over high-capacity Wireless Technology utilizing licensed LMDS spectrum. The Company’s operating subsidiaries are licensed CLEC and Wireless Cable Operators providing High-Capacity Broadband services.

Hammer Fiber serves residential and small business markets with high-capacity broadband, voice and video through direct fiber and its wireless fiber platform, Hammer Wireless® AIR technology. Hammer Fiber’s Fiber Optic network covers the bulk of New Jersey. It connects major cities like Philadelphia and New York.

Hammer Fiber has developed many products that take advantage of this network and its capabilities to offer Internet based services to an array of diverse verticals. The Company offers consumer products including internet, voice, and video service. It also offers enterprise solutions, such as managed hosting, data transport and storage; as well as carrier grade offers such as low latency dark and lit fiber routes.

Hammer Fiber has announced the expansion of its IAAS cloud services to include support for the Cryptocurrency and Blockchain industry. The expanded service will permit these companies to host their products over Hammer Fiber's strong and modern server infrastructure, fiber network architecture and data center presences in some of the most secure buildings in the New York, New Jersey and Philadelphia area.

Hammer Fiber also previously announced that it will be expanding its network infrastructure within the city limits of Atlantic City in support of increasing demand from customers for server space located within the township. The increase in demand is largely in response to New Jersey's legislation concerning the online sports fantasy business.

This new legislation requires Daily Fantasy Sports (DFS) operators to have physical hardware within Atlantic City town limits. Hammer Fiber will start to increase its server capacity as part of a plan to strengthen its overall network presence in Atlantic City.

Hammer Fiber also previously announced the launch of its Virtual Private Network (VPN) service. Customers of this service connect and use the internet via their own encrypted connection and Hammer Fiber's VPN servers. This allows them private, unrestricted access.

Hammer Fiber Optic Investments Ltd. (HMMR), closed Monday’s trading session at $0.657, up 31.4%, on 170,016 volume. The average volume for the last 3 months is 170,016 and the stock's 52-week low/high is $0.096500001/$1.41999995.

Edesa Biotech, Inc. (EDSA)

QualityStocks, TradersPro, StockMarketWatch, BUYINS.NET, Schaeffer's and MarketClub Analysis reported earlier on Edesa Biotech, Inc. (EDSA), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Edesa Biotech, Inc. is a clinical-stage biopharmaceutical company listed on the NasdaqGS. Its focus is on efficiently developing innovative treatments that address significant unmet medical needs. The Company’s lead product candidate is EB01. Late-stage drug candidates developed by Edesa Biotech aim to help patients with limited treatment options for dermatological and gastrointestinal diseases. Edesa Biotech is headquartered in Markham, Ontario. Established in 2015, the Company also has U.S. offices in Southern California in Port Hueneme.

Experts in the field of dermatology and gastroenterology founded Edesa Biotech. The Company’s EB01 is a novel non-steroidal anti-inflammatory molecule (sPLA2 inhibitor) for the treatment of chronic allergic contact dermatitis that has demonstrated statistically significant improvements in manifold clinical studies. In October of 2019, a Phase 2b clinical study of EB01 was started.

The design of sPLA2 inhibitors are to inhibit the inflammatory process at its inception rather than after inflammation has occurred. Furthermore, Edesa’s intention is to expand the utility of its sPLA2 inhibitor technology across numerous indications and also expand its portfolio with assets that can drive long-term growth opportunities.

Edesa’s intention is to expand its pipeline across multiple indications. This could include acne or other inflammatory disorders. For instance, EB02 is a formulation developed to treat hemorrhoids. Also, the Company has licensed other technology. Edesa is in talks to broaden its portfolio with investigational medicines to treat other serious skin and gastrointestinal conditions.

Recently, Edesa Biotech announced a collaborative research project with the National Research Council of Canada (NRC) to develop novel immunotherapies for vitiligo and other indications. Vitiligo is a life-altering autoimmune disease that results in the depigmenting of the skin.

With this agreement, NRC scientists will produce numerous monoclonal antibodies for Edesa Biotech to identify a lead candidate to take into IND-enabling studies. The NRC will grant Edesa an exclusive global license for the antibodies arising from the project. Edesa expects to complete the initial phase of the project by the end of this year.

Edesa Biotech previously announced a strategic agreement with Light Chain Bioscience (a brand of NovImmune SA), a foremost Swiss pharmaceutical development company, for an exclusive global license to develop and commercialize two Phase 2-ready biologic drug candidates for all therapeutic, prophylactic, and diagnostic applications.

The monoclonal antibodies licensed from Light Chain Bioscience block certain signaling proteins, called TLR4 and CXCL10. Edesa Biotech plans to pursue the development of these signaling molecules as potential treatments for acute respiratory distress syndrome and lung injury resulting from viral respiratory infections, such as the coronavirus that causes COVID-19, and other disorders.

Edesa Biotech, Inc. (EDSA), closed Monday’s trading session at $11.92, up 102.7211%, on 161,206,097 volume. The average volume for the last 3 months is 161.206M and the stock's 52-week low/high is $4.05480003/$12.00.

LQwD Fintech Corp. (LQWDF)

We reported earlier on LQwD Fintech Corp. (LQWDF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

LQwD Fintech (TSXV: LQWD) (OTC: LQWDF), a Lightning Network-focused company, has announced that the company will be presenting a real-time, interactive presentation on VirtualInvestorConferences.com. LQwd Fintech CEO Shone Anstey will present live on the conference site on Sept. 21, 2021, at 4 p.m. ET. The live, interactive online event is a forum for interested individuals, including current and potential investors as well as analysts and advisors, can learn more about the company as well as ask questions in real time. An archived webcast of the presentation will also be available following the event. Attendees are encouraged to pre-register and run the online system check to ensure participation.

To view the full presentation, visit https://ibn.fm/LnmmS

To view the full press release, visit https://ibn.fm/2B2zo

LQwD is a Lightning Network-focused company developing payment infrastructure and solutions. The company's mission is to develop institutional-grade services that support the Lightning Network and drive improved functionality, transaction capability, user adoption and utility, and scaling Bitcoin. LQwD also holds Bitcoin as an operating asset establishing nodes and payment channels across the Lightning Network. For more information, please visit www.LQwDFintech.com.

LQwD Fintech Corp. (LQWDF), closed Monday’s trading session at $0.2614, off by 15.5262%, on 2,643 volume. The average volume for the last 3 months is 2,643 and the stock's 52-week low/high is $0.088299997/$4.00.

The QualityStocks Company Corner

Asia Broadband Inc. (OTC: AABB)

The QualityStocks Daily Newsletter would like to spotlight Asia Broadband Inc. (AABB).

  • Asia Broadband (OTC: AABB),a resource company focused on the production, supply and sale of precious and base metals primarily to Asian markets, has reached the final development stages of its soon-to-be-launched proprietary cryptocurrency exchange, which will be available in the AABB Wallet. The company noted that the scope of the Exchange project has changed and grown significantly tremendously over the past several months as the AABB Wallet now has more than 14,000 AABB Wallet user downloads and 260,000 lines of development code written. With this context in mind, features and capabilities that have been added include expanded functionality and usability as well as module additions. Currently the company plans to roll out the Exchange in a strategic plan throughout the coming weeks. To view the full press release, please visit https://ibn.fm/Te9ja
  • Since the height of the pandemic, the price of gold has been hitting record highs. Last week, the price of gold also rose after the publication of lower than expected nonfarm payrolls. However, this was short lived as the price declined later in the week, falling below $1,800 on Wednesday. This decline is bearish for the yellow metal and shows its inability to maintain gains in the current environment, which displays the metal’s innate weakness. It should be noted that the recent drop in gold prices was at least partly brought about by new developments in the financial markets, such as the rise in bond yields and the U.S. dollar strengthening. To rally decisively, gold requires more than the delaying of tapering by the Federal Reserve. Until this occurs, the metal is likely to continue struggling. While day traders may call such fluctuations “struggling,” precious metals sector players such as Asia Broadband Inc. (OTC: AABB) are unlikely to be fazed by those day-to-day market adjustments since they are in the game for the long haul.

Asia Broadband Inc. (OTC: AABB) is a resource company focused on the production, supply and sale of precious and base metals, primarily to Asian markets.

The company utilizes its specific geographic expertise, experience and extensive industry contacts to facilitate its innovative distribution process from the production and supply of precious and base metals in Mexico to client sales networks in Asia. This vertically integrated approach to sales transactions differentiates Asia Broadband from its competitors in the mining space.

Development Program in Colima, Mexico

In October 2020, Asia Broadband announced its acquisition of a high potential mineral property in the state of Colima, Mexico. Per the press release, previous geophysics and groundwork have revealed strong indications of significant mineralization in multiple sectors of the property.

The company recently began the construction of exploration and development facilities and infrastructure roads on its Colima property, and plans are underway to extend previous geophysics and groundwork on the property. In January 2021, Asia Broadband announced its allocation of $10 million for the initial development program, with the aim of accelerating operations at the Colima site toward production.

Positioned in a major gold-iron-copper production area, the company’s Colima property is situated approximately 25 kilometers east of the Pena Colorada mine in Minatitlan, Mexico. It is advantageously located, with direct access to main Highway #3, and the property also has an essential natural water supply.

AABB Gold Token

In December 2020, Asia Broadband announced its entry into a definitive development agreement with Core State Holdings Corp., a digital assets and crypto wallet creator, to produce a white label gold-backed cryptocurrency coin. The AABB Gold token is an ERC-20 token being developed on the Ethereum blockchain.

In a February 2021 news release, the company provided a development update on the cryptocurrency token, noting that Core State Holdings Corp. “is continuing to modify the set-up and move through the final stages of testing of the iOS and Android AABB Wallet applications, including the implementation of an application interface to allow users to see the real-time exchange rate of gold that backs the price of the AABB Gold token set at one-tenth of a gram or approximately $5.80 USD.”

Core State Holdings Corp. has also continued to enhance www.AABBGoldToken.com, which the company notes will be the go-to knowledge base for all information concerning the soon-to-be launched AABB Wallet and AABB Gold token.

AABB’s primary goal for the token is to become a worldwide standard of exchange – secured and trusted with gold backing – by expanding circulation and targeting large population and high growth markets globally, including China and East Asia.

Asia Broadband Inc. (AABB), closed Monday’s trading session at $0.11525, up 2.2626%, on 52,537,214 volume. The average volume for the last 3 months is 52.537M and the stock's 52-week low/high is $0.0026/$0.658999979.

Recent News

Lottery.com

The QualityStocks Daily Newsletter would like to spotlight Lottery.com.

Trident (NASDAQ: TDAC, TDACU, TDACW), a special purpose acquisition company, today announced that it has filed an amended Form S-4 (the “Registration Statement”) with the Securities and Exchange Commission (“SEC”) in relation to its proposed business combination with AutoLotto Inc. (“Lottery.com”), a leading technology company that is transforming how, where and when the lottery is played. This Registration Statement includes additional information related to Trident’s proposed business combination with Lottery.com, including Lottery.com’s second quarter 2021 financial statements. To view the full press release, visit https://ibn.fm/EnzpO

Lottery.com is a next generation platform where consumers can play the lottery online – in browser or via smartphone app. The platform offers users access to official lottery games sanctioned by their individual states and also provides lottery data to more than 400 digital publishers, including Google and Amazon Alexa.

Lottery.com was founded in 2015, launching at the LAUNCH festival and soon turning into a leader in the industry. With headquarters in Austin, Texas, the company is dedicated to helping advance the lottery industry into the digital age and works closely with state regulatory bodies to achieve this goal.

The company recently entered into a definitive agreement for a business combination with special purpose acquisition company Trident Acquisitions Corp. (NASDAQ: TDAC) (“Trident”), which will result in Lottery.com becoming a publicly listed company. Once the transaction is complete, the combined company will be trademarked as Lottery.com, with its common stock to remain listed on Nasdaq under ticker symbol ‘LTRY’.

Lottery.com Online Platform

The Lottery.com online platform works closely with state regulators, advancing the lottery into the digital age. With the online platform, the company offers enhanced regulatory capabilities by leveraging innovative blockchain technology and capturing the untapped market of digitally native players.

Players go online in a browser or through a mobile application to use the interface. The process includes:

  • Players Choose a Game: Players can play officially state sanctioned multi-state games and other games offered in the states in which they live. Players can also find winning numbers, jackpot totals, draw dates and more for hundreds of other lottery games around the world.
  • Players Pick Numbers: Players can play their lucky numbers or do a quick pick of randomized numbers in as simple as two taps. “Tap, Tap, Ticket!”
  • A Safe and Secure Way to Play: Purchases for up to 50 tickets can be made at one time through the online interface. Lottery.com handles everything after purchase, letting users know when they win.
  • Collect All Winnings: Consumers keep 100% of their winnings. All winnings stay in the Lottery.com balance for future ticket purchases, or a cashout can be requested. Company representatives contact winners who hit big jackpots, instructing them on the redemption process.

A Better Way to Play the Lottery

Lottery.com has an innovative e-commerce platform that is using blockchain to maintain an accurate ledger. From 2016 to 2020, Lottery.com grew gross revenue at a CAGR of 363%, and it forecasts gross revenue equal to approximately $71 million in 2021, $279 million in 2022, and $571 million in 2023.

Lottery.com is leveraging a successful playbook, with $398 billion in global lottery sales but only 6.7% online penetration. The large market opportunity is expected to shift to online transactions within the next decade.

The platform is currently available in 12 states across the United States, and the company plans to expand to 34 by the end of 2023. Global expansion is also on the horizon, with partnership plans in Turkey and Ukraine.

Key features that make the Lottery.com experience unique include:

  • All the Games Users Love – For consumers who live in applicable LIVE states, Powerball and Mega Millions are available right from the mobile application.
  • Convenience – Lottery.com makes playing the lottery on mobile devices easy. After setting up an account, users can begin playing in moments or set reminders to play when the jackpot is high.
  • Easy Cashouts – Users can cash out winnings straight to a bank account, safely and securely, with no commissions.

The company is also gamifying charitable giving, fundamentally changing how nonprofits engage with donors and raise funds. WinTogether.org is a platform designed to offer charitable donation sweepstakes to incentivize donors to take action by offering large cash prizes and once-in-a-lifetime experiences.

Strong Advisory Board Presence

Lottery.com is expected to continue to gain support, leaning on the experience of its advisory board and notable investors from the venture capital, gaming and entertainment industries. These include:

  • Jason Robins, CEO of DraftKings Inc. (NASDAQ: DKNG)
  • Ben Narasin, Venture Partner of NEA
  • Peter Diamandis, Chairman of XPRIZE Foundation
  • Matthew Le Merle, Co-Founder and Managing Partner of Fifth Era and Keiretsu Capital
  • Paraag Marathe, President of Enterprises and EVP of Football Operations for the San Francisco 49ers
  • Jamie Gold, The Poker Philanthropist

Management Team

Tony DiMatteo is the Co-Founder and Chief Executive Officer of Lottery.com. He is a serial entrepreneur and highly sought-after industry speaker and thought leader. He has been featured in The Wall Street Journal, Forbes, VentureBeat, TechCrunch Inc. and more for his approach to entrepreneurship, the gaming industry and cryptocurrency.

Matt Clemenson is the Co-Founder and Chief Commercial Officer of Lottery.com. He is responsible for the company’s strategy. Mr. Clemenson was steeped in corporate and enterprise engineering processes at Hotwire and Expedia before going on to be CEO at LesConcierges, the world’s largest concierge company, which merged into John Paul and sold to Accor Hotels. Clemenson and DiMatteo have been partners for more than 10 years.

Ryan Dickinson is the company’s President and Chief Operating Officer. He has a diverse background in business, technology, product, design and sales, which has aided him in producing many successful outcomes throughout his career. Notably, as Senior Vice President of a SaaS company, Mr. Dickinson produced profitability from a negative $1.4 million division within the first year by reinventing the product offerings, streamlining processes and establishing a go-to-market strategy. Additionally, he produced three record breaking revenue years in a row for AccuWeather, the world’s largest weather provider, by increasing every KPI for all flagship properties by no less than 5%.

Luc Vanhal is the company’s Chief Financial Officer. He has served in C-level executive roles since the 1990s, including a nine-year tenure for The Walt Disney Company (NYSE: DIS) from 1990 to 1999. From 2001 to 2004, he managed the development of the World of Warcraft massively multiplayer game, which, by the end of 2020, still had over five million active subscribers. As the CFO of Lottery.com, Mr. Vanhal leads the company’s global finance organization, with treasury responsibility, accounting, analysis and financial planning.


Recent News

chart

Tingo Inc. (OTCQB: IWBB)

The QualityStocks Daily Newsletter would like to spotlight Tingo Inc. (IWBB).

  • Dozy Mmobuosi, CEO and co-founder of Tingo Mobile, aims to accelerate digital commerce in Agritech and Fintech verticals across Africa
  • Mmobuosi spearheaded the design and launch of Nigeria’s first SMS banking solution and has led Tingo’s growth to more than $600 million in annual revenue
  • Tingo’s innovative mobile Agritech and Fintech platforms and credit solutions bolster commerce, connect markets and provide mobile banking services
  • Due to growing need and demand, Mmobuosi expects Tingo Mobile to become the continent’s leading Agri-Fintech business powered through smartphone technology
Dozy Mmobuosi founded Tingo Mobile in 2001 to bring mobile technology and Fintech solutions to the unbanked rural areas in Nigeria. Mmobousi’s first Fintech endeavor was a revolutionary SMS banking solution which represented the first mobile payment platform in Nigeria which remains in use today. 

Tingo Inc. (OTCQB: IWBB) is a digital service agri-fintech technology company focused on foundation-level agriculture and related financial services in Africa. The company aims to be Africa’s leading agri-fintech player, transforming rural farming communities to connect through its proprietary platform to meet their complete needs – from inputs and agronomy to off take and marketplace – and deliver sustainable income in an impactful way. The company’s vision is to build complete digitally inclusive ecosystems that promote financial inclusion and deliver disruptive micro-finance solutions, empower societies, produce social upliftment in rural communities and open international opportunities.

Tingo believes that a truly connected world will help contribute to a better global society. The company’s core focus areas are telecoms, financial services/fintech and agritech. Tingo’s goal is to provide a best-in-class customer experience, support the domestic economies of its host countries and support technological and financial inclusion to end the poverty premium. Through this, Tingo hopes to deliver attractive returns to shareholders while investing in the long-term future of the company and its subsidiaries.

Global climate change is challenging sustainable production and food security. Tingo’s strategy and market execution provide an opportunity for Africa to be a core focal point to solve a number of key areas of concern, including food security, gender equality, financial inclusion and poverty alleviation, to name a few. Disruption of micro finance through the use of DeFi-based stable coins and smart contracts will give agri-communities access to capital markets-driven digital finance solutions that make them more competitive and sustainable economically, striking a good balance of returns between digital asset providers and Tingo as the service partner. This innovation will deliver significant access to much needed finance at ‘Grassroot’ levels, delivering tangible social upliftment and GDP growth in the African markets served by Tingo.

Tingo Mobile, with more than nine million subscribers, is Nigeria’s leading technology and device-as-a-service platform aimed at accelerating digital commerce, especially in the country’s agritech and fintech verticals. The company helps farmers acquire mobile phones through a unique leasing plan, connecting them to mobile and data networks through its own virtual mobile network. Tingo also connects farmers to markets, services and resources via Nwassa, its digital agritech marketplace platform that commenced operations in 2020. The company has also launched a beta version of TingoPay – a B2B and B2C fintech app aimed at providing financial services to users inside and outside of the agriculture value chain. Among the services offered are mobile wallets, payment processing and access to specialist lenders, insurers and pension products.

Tingo will soon announce its innovative blockchain-based solution for use of digital stable coins to empower frictionless trade across borders in Africa. The company’s market-proven model in Nigeria is its core foundation, enabling Tingo to deliver the same service model across Africa to become the continent’s leading agri-fintech business powered through smartphone technology.

The African Continental Free Trade (ACFT) plan will be a key framework to prepare the company to be the leading intra-Africa trading hub for trade flows across Africa in the medium term, when it is likely the agreement will be executed into tangible activity. Tingo is well positioned to easily transform the goals of the ACFT into reality when finally implemented by the African Union and the various African countries that have not signed up.

Tingo posted total revenue of $594 million in 2020, with $212 million EBITDA. As of December 31, 2020, Tingo has 9,344,000 subscribers. The company is confident that these figures will grow through its expansion across Africa and natural progression of business in Nigeria.

Businesses

Tingo has four core businesses:

  • Mobile Phone Leasing – Tingo has distributed almost 30 million mobile handsets since 2014 and will continue to replace the devices of its installed customer base every three years. Tingo Mobile provides the latest mobile phone handsets at an affordable price point and allows customers to spread payments over 36 months.
  • Mobile Voice and Data Service – Through a mobile virtual network, Tingo provides its customers with voice and data services, allowing customers to communicate effectively, both inside and outside the agricultural ecosystem.
  • Nwassa Marketplace Platform – Nwassa is Tingo’s proprietary agritech platform which provides Africa’s farmers with access to global markets to secure more competitive pricing for their crops. The platform processes 500,000 daily transactions with a value of over $8 million. A select group of trusted partners can assist smallholder farmers and agricultural cooperatives with packaging, warehousing, and dry and wet cargo logistics, as well as up-to-date information from the global agricultural sector. Tingo provides its customers with digital wallet services, which enable them to send and receive domestic payments, monitor cash flow in real time and securely hold money. The company also provides access to other services, such as utility bill payment, virtual airtime top-up, insurance services and alternative lending solutions.
  • TingoPay – Since the launch of the Nwassa platform, Tingo has been a dominant player in the B2B fintech vertical. After many successful months of operating Nwassa, Tingo entered the fintech B2C vertical to extend its B2B offering to a broader market beyond agriculture.

TingoPay is still in its beta phase and will launch in 2021 with a comprehensive marketing campaign. TingoPay offers the following services:

  • Tingo Wallet top-up
  • Peer to Peer payments, inclusive of merchant payments at the stores
  • Utility payments – airtime, broadband, cable, electricity, water, hotel, flights etc.
  • Pension payments
  • QR code payment services

Market Opportunity

Africa is the second-largest continent by population. It is also the youngest by far, with a median age of 18 for its 1.3 billion people. Tingo believes the building blocks for growth in Africa’s agriculture industry are in place and that the company is well positioned to participate in the upside. Sub-Saharan Africa’s population is growing at a rate of 2.7 percent per year. At the current growth rate, the continent’s population will double by 2050. Africa’s youthfulness represents a significant opportunity for material growth in demand for agricultural commodities. This younger generation is also being born into a digital world and is comfortable using technology.

Africa’s governments are improving business conditions for entrepreneurs and small businesses. Sub-Saharan Africa’s World Bank Doing Business rank has improved from 45 in 2004 to 65 in 2020. Tingo believes this trend will continue and encourage establishment of more new ventures across all economic sectors, including agriculture.

Africa attracted $407 billion of Foreign Direct Investments (“FDI”) between 2014 and 2018. Investments are increasingly focused on services and industrial sectors. Only 20 percent of investments are in extractive industries – a clear reversal from 2008, when 55 percent of FDI was aimed at resource extraction. Tingo believes FDI into Africa will help resolve significant infrastructure constraints and create value for agribusiness.

Management Team

Dozy Mmobuosi is the CEO of Tingo. He cofounded Tingo Mobile PLC (Nigeria) in 2001 and led the design and launch of Nigeria’s first SMS banking solution, which is still in use in the country today. He also headed a team of more than 120 Chinese and Nigerian engineers in the construction of two mobile phone assembly plants in Nigeria, which have produced and distributed 20 million phones across the country. He has led Tingo’s growth to more than $600 million in revenue annually. He holds a Ph.D. in Rural Advancement from UPM Malaysia.

Dakshesh Patel is the CFO of Tingo. He was formerly CFO of NatWest’s Global Debt and Investment Banking division. He has served as a Director at Gerken Capital Associates, a San Francisco-based alternative asset fund manager. He also led the restructure of Lloyds Banking Group (last financial crisis); managed integration of two leading shipping groups’ global treasury function to create world-leading shipping group Maersk Shipping; built three fintech companies; and exited one to Worldpay. Mr. Patel has strong banking experience, with a focus on Africa. He is a chartered accountant.

Chris Cleverly is president of Tingo. He has served as CEO of the Made in Africa Foundation, and as CEO of blockchain payments gateway startup Kamari. He has been a board member of several companies, both public and private, in the UK, India, China and Africa. He has advised multiple UK companies on their entrance into African markets, and regularly advises the UK Government on development issues and African governments on investment issues.

Clarence Simms is the Chief Technology Officer at Tingo. He has 25 years of IT and IT management experience. He has worked in IT Shared Services Technical Operations and IT Program Management for Huawei Technologies and MTN. As an entrepreneur, he created Africaprepay.com, a service that allows African Diaspora travelers to send airtime, pay bills, send mobile money and transfer money to a bank account from anyplace in the world.

Rory Bowen is the Chief of Staff at Tingo. Mr. Bowen started his career in traditional capital and derivatives markets working for Moneycorp and Tradition UK in European and emerging markets across FX, interest rate derivative and government bond markets. He has also spent time with one of Europe’s fastest growing fintech’s banking circles. Before joining Tingo, he was Chief of Staff at FinTech Alliance, an organization established in partnership with the UK Government Department for International Trade to foster innovation, growth and foreign direct investment (FDI) in the financial services sector and facilitate greater public/private cooperation.

Tingo Inc. (OTCQB: IWBB), closed Monday’s trading session at $2.45, off by 2%, on 5,753 volume. The average volume for the last 3 months is 5,753 and the stock's 52-week low/high is $1.50/$8.97999954.

Recent News

InMed Pharmaceuticals Inc. (NASDAQ: INM)

The QualityStocks Daily Newsletter would like to spotlight InMed Pharmaceuticals Inc. (NASDAQ: INM).

InMed Pharmaceuticals (NASDAQ: INM), a leader in the manufacturing and clinical development of rare cannabinoids, has announced that it will release its fiscal year 2021 financial report at the end of the week. INM’s full financial statements and related MD&A for the period ending June 30, 2021, will be released on Friday, Sept. 24, 2021. In connection with the release of its financial report, the company will also be hosting a conference call/webcast to discuss the report. The call will begin at 11 a.m. ET. Interested individuals from the United States and Canada can call toll free at 855-605-1745; those who are interested and need to dial in internationally can call 914-987-7959. To view the full webinar, visit https://ibn.fm/8h0xJ. To view the full press releases, visit https://ibn.fm/XKM71 and https://ibn.fm/gi8O6.

InMed Pharmaceuticals Inc. (NASDAQ: INM) is a global leader in the manufacturing and clinical development of rare cannabinoids. InMed is a clinical stage company developing cannabinoid-based pharmaceutical drug candidates, as well as manufacturing technologies for pharmaceutical-grade rare cannabinoids.

The company is dedicated to delivering new therapeutic alternatives to treat conditions with high unmet medical needs. The company is also developing a proprietary manufacturing technology to produce pharmaceutical-grade rare cannabinoids in the lab and has recently announced an LOI to acquire a leading rare cannabinoid manufacturer.

Research and Technology

There are more than 100 rare cannabinoids found in only trace amounts in the cannabis plant, together making up less than 1% of the plant’s biomass. InMed is initially focused on the therapeutic benefits of cannabinol (CBN) in diseases with high unmet medical need. Preclinical studies of CBN demonstrated an excellent safety profile and showed CBN has potential for therapeutic benefit over other cannabinoids such as tetrahydrocannabinol (THC) and cannabidiol (CBD).

Evidence suggests there may be great therapeutic potential in rare cannabinoids. Each has a specific chemical structure, and different cannabinoids have been observed to have distinct physiological properties in humans, including therapeutic potential for specific diseases as well as unique safety profiles. CBN is the active pharmaceutical ingredient (API) in InMed’s two lead programs for dermatological and ocular diseases.

InMed’s most advanced compound, INM-755, is a CBN topical cream under clinical development for the treatment of epidermolysis bullosa, a severe genetic skin disorder. To date, INM-755 has been evaluated in two Phase 1 clinical trials in healthy volunteers. InMed has filed Clinical Trial Applications in several countries as part of a global Phase 2 clinical trial of INM-755 (cannabinol) cream in epidermolysis bullosa. Responses from the National Competent Authorities and Ethics Committees are expected throughout the summer of 2021.

InMed is also involved in developing INM-088, an ocular CBN formulation being researched for the treatment of glaucoma, the second leading cause of blindness in the developed world. InMed is currently evaluating several formulations to deliver CBN into the eye to address issues of dosing frequency, side effects and treatment penetration. INM-088 is being designed for topical delivery to the eye. This localized delivery results in very little drug being absorbed or migrating into the bloodstream, thus minimizing potential adverse side effects. INM-088 shows promise to reduce intraocular pressure and provide neuroprotection of the eye.

Manufacturing

The limited availability of rare cannabinoids like CBN makes them economically impractical to extract directly from the plant for pharmaceutical use. InMed is developing IntegraSyn, a cannabinoid synthesis manufacturing system to create rare cannabinoids in the lab that are bioidentical to the compounds derived from the cannabis plant. IntegraSyn uses multiple standard pharmaceutical processes and has achieved a cannabinoid yield of 5 grams per liter, surpassing commercial viability and significantly exceeding currently reported industry yields. InMed is now focusing on manufacturing scale-up to larger batch sizes while continuing process optimization, targeting increased cannabinoid yield and further reducing overall cost of goods.

BayMedica Inc. Acquisition

On June 29, 2021, InMed announced it had entered into a non-binding letter of intent to acquire BayMedica Inc., a private company based in Nevada and California that specializes in the manufacture and commercialization of rare cannabinoids.

As noted in the news release, BayMedica is a revenue-stage biotechnology company leveraging its significant expertise in synthetic biology and pharmaceutical chemistry to develop efficient, scalable and proprietary manufacturing approaches to produce high quality, regulatory-compliant rare cannabinoids for consumer applications. BayMedica is currently commercializing the rare cannabinoid CBC (cannabichromene) as a B2B supplier to distributors and manufacturers marketing products in the health and wellness sector. BayMedica is planning additional rare cannabinoid launches for the coming year.

Pursuant to the indicative terms of the LOI, InMed and BayMedica intend to negotiate and enter into a definitive agreement under which InMed would acquire 100% of BayMedica in exchange for 1.6 million InMed common shares to be issued to BayMedica’s equity and convertible debt holders, with any such issued InMed common shares being subject to a six-month contractual hold period.

Market Outlook

There is a rapidly growing demand for rare cannabinoids. However, their low natural concentration makes traditional harvesting of these compounds cost prohibitive. Biosynthesis allows production of rare cannabinoids in the lab that are bioidentical to compounds found in nature, with significantly higher yields which reduce costs. Biosynthesis can produce pharmaceutical-grade, bioidentical, THC-free compounds at a cost that’s 70 to 90 percent less than wholesale prices of naturally harvested rare cannabinoids.

Cannabinoid-based pharmaceuticals are expected to overtake the market as rare cannabinoids become less expensive and more available. According to Statista, the value of the consumer market for cannabinoid-based pharmaceuticals in the United States is forecast to grow to $25 billion by 2025 and to $50 billion by 2029, with cannabinoid-based pharmaceuticals used to treat health conditions including pain, respiratory conditions, autoimmune conditions and more.

Management Team

Eric A. Adams has been CEO and president of InMed since June 2016. He has more than 25 years of experience in establishing corporate entities, capital formation, global market development, mergers and acquisitions, licensing and corporate governance. He previously served as CEO at enGene Inc. Prior to enGene, he held senior positions in global market development with QLT Inc. (Vancouver), Advanced Tissue Sciences Inc. (La Jolla, CA), Abbott Laboratories (Chicago, IL) and Fresenius AG (Germany).

Bruce S. Colwill is InMed’s CFO. He has more than 25 years of financial leadership experience in public and private companies. Prior to InMed, he served as CFO of General Fusion Inc., a private clean energy company. He was also CFO at Entrée Resources Inc., a mineral exploration company, from 2011 to 2016. He has held CFO roles at Neuromed Pharmaceuticals Ltd., Response Biomedical Corp, Forbes Medi-Tech Inc. and Euronet Worldwide Inc.

Alexandra D.J. Mancini is Senior Vice President, Clinical and Regulatory Affairs at InMed. She has more than 30 years of global biopharmaceutical research and development experience. She has been an executive with numerous biotech companies, including senior vice president of Clinical and Regulatory Affairs at Sirius Genomics; senior vice president of Clinical and Regulatory Affairs at INEX Pharmaceuticals; and vice president of Regulatory Affairs at QLT Inc.

Eric C. Hsu is Senior Vice President, Pre-Clinical Research and Development at InMed. He joined InMed with more than 18 years of scientific leadership experience in the field of gene therapy. He has held various positions within enGene Inc., including vice president of Research and vice president of Scientific Affairs and Operations. He received his Doctorate from the Department of Medical Biophysics at the University of Toronto.

Michael Woudenberg is Vice President, Chemistry, Manufacturing and Controls at InMed. He has more than 20 years of successful drug development, process engineering, GMP manufacturing and leadership experience. He has held positions with 3M, Cardiome Pharma, Arbutus Biopharma and, most recently, was Managing Director of Phyton Biotech LLC.

InMed Pharmaceuticals Inc. (INM), closed Monday’s trading session at $1.94, off by 2.5126%, on 1,040,362 volume. The average volume for the last 3 months is 1.04M and the stock's 52-week low/high is $1.89999997/$6.42000007.

Recent News

CNS Pharmaceuticals Inc. (NASDAQ: CNSP)

The QualityStocks Daily Newsletter would like to spotlight CNS Pharmaceuticals Inc. (NASDAQ: CNSP).

A study led by researchers from the Arnold School of Public Health at the University of South Carolina has discovered that in comparison to patients lacking continuity of care, individuals with continuity in their primary health care have lower mortality rates. The study was published in the “Health Services Research” journal. Fortunately, cancer care is improving at a high rate. An example is the work being done by CNS Pharmaceuticals Inc. (NASDAQ: CNSP), which is focusing all its attention on developing novel remedies for primary plus metastatic cancers, especially those impacting the central nervous system as well as the brain.

CNS Pharmaceuticals Inc. (NASDAQ: CNSP) is a clinical stage biotechnology company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system.

The company was founded in 2017 and is headquartered in Houston, Texas.

Organ Targeted Therapeutics

The company’s lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. Berubicin also has potential to treat other central nervous system malignancies. Based on limited clinical data, Berubicin appears to be the first anthracycline to cross the blood brain barrier in the adult brain, and it was the subject of a successful Phase 1 study which found the MDT and produced efficacy data as well.

CNS holds a worldwide exclusive license to the Berubicin chemical compound. The company has acquired all requisite data and know-how from Reata Pharmaceuticals Inc. related to a completed Phase I clinical trial of Berubicin in malignant brain tumors. In this trial, 44% of patients experienced a statistically significant improvement in clinical benefit. In 2017, CNS entered into a collaboration and asset purchase agreement with Reata.

CNS intends to explore the potential of Berubicin to treat other diseases, including pancreatic and ovarian cancers and lymphoma. The company is also examining plans to develop combination therapies that include Berubicin.

CNS estimates that more than $25 million in private capital and grants were invested in Berubicin prior to the company’s $9.8 million IPO in November 2019.

CNS intends to submit an IND for Berubicin during the fourth quarter of 2020 and expects to commence a Phase II clinical trial of Berubicin for the treatment of GBM in the U.S. in Q1 2021. A sub-licensee partner was awarded a $6 million EU/Polish National Center for Research and Development grant to undertake a Phase II trial of Berubicin in adults and a first-ever Phase I trial in pediatric GBM patients in Poland in 2021.

The company’s second drug candidate, WP1244, is a novel DNA binding agent licensed from the MD Anderson Cancer Center. In preclinical studies, WP1244 proved to be 500-times more potent than the chemotherapeutic agent, daunorubicin, in inhibiting tumor cell proliferation. The company has entered into a sponsored research agreement with the MD Anderson Cancer Center to further the development of WP1244.

CNS Pharmaceuticals recently engaged U.S.-based Pharmaceutics International Inc. and Italian BSP Pharmaceuticals SpA for the production of the Berubicin drug product. The company has implemented a dual-track manufacturing strategy to mitigate COVID-19-related risks, diversify its supply chain and provide for localized availability of Berubicin. CNS has already completed synthesis of Berubicin’s active pharmaceutical ingredient (API) and has shipped the API to both manufacturers in order to prepare an injectable form of Berubicin for clinical use.

Global Brain Tumor Therapeutics Market

The high recurrence rate of malignant brain tumors is due to reappearance of focal masses, indicating that a sub-population of tumor cells in these cancers may be insensitive to current therapies and may be responsible for reinitiating tumor growth. This necessitates the development of newer drugs in the market that demonstrate greater efficacy in treating such aggressive cancers.

A global increase in neurological disorders has placed increased attention on cancers of the brain over the past decade. Neurological disorders are becoming one of the most prevalent types of disorders, due to longer life expectancy, greater exposure to infection and an increasingly sedentary lifestyle. Because few treatments for primary and metastatic cancers of the brain exist, costs are high and have acted as a restraint for the brain tumor therapeutics market.

Despite progress in surgery, radiotherapy and chemotherapeutic strategies, effective treatments for brain cancer are limited by a lack of specific therapies for the brain and the difficulty in transporting therapeutic compounds across the blood brain barrier. Therefore, there is a significant need for novel and effective therapeutic drugs and strategies that prolong survival and improve quality of life for brain tumor patients.

Several companies are making significant investments into R&D, which is expected to bring more treatment options to the market in the near future. Industry reports consistently project continued growth in the market.

One report estimates that the global brain tumor therapeutics market will reach a valuation of $2.74 billion in 2023, with the market expected to register a CAGR of 11% during the forecast period from 2018 to 2023. Another report projects that the global brain tumor therapeutics market will reach $3.4 billion by 2025, up from $2.25 billion in 2019 (http://nnw.fm/eDUjp).

Management Team

John M. Climaco is the CEO of CNS Pharmaceuticals. For 15 years, Climaco has served in leadership roles for a variety of health care companies. Recently, Climaco served as the Executive Vice President of Perma-Fix Medical S.A, where he managed the development of a novel method to produce Technitium-99. Climaco also served as President and CEO of Axial Biotech Inc., a DNA diagnostics company. In the process of taking Axial from inception to product development to commercialization, Climaco forged strategic partnerships with Medtronic, Johnson & Johnson and Smith & Nephew.

Christopher Downs, CPA, is the company’s Chief Financial Officer. Downs previously served as Interim Chief Financial Officer and Executive Vice President of InfuSystem Holdings Inc. (NYSE: INFU), a supplier of infusion services to oncologists in the United States. Downs holds a Bachelor of Science from the United States Military Academy at West Point, an MBA from Columbia Business School and a Master of Science in Accounting from the University of Houston-Clear Lake.

Dr. Donald Picker is the Chief Scientific Officer of CNS. Picker has over 35 years of drug development experience. Prior to joining CNS, Picker worked at Johnson Matthey, where he was responsible for the development of Carboplatin, one of the world’s leading cancer drugs, which was acquired by Bristol-Myers Squibb with annual sales of over $500 million. In addition, he oversaw the development of Satraplatin and Picoplatin, third-generation platinum drugs currently in late-stage clinical development.

Sandra L. Silberman, M.D., Ph.D., is the Chief Medical Officer of CNS Pharmaceuticals. Silberman is a hematologist/oncologist who earned her B.A., Sc.M. and Ph.D. from the Johns Hopkins University School of Arts and Sciences, School of Public Health and School of Medicine, respectively, and her M.D. from Cornell University Medical College. She then completed both a clinical fellowship in hematology/oncology and a research fellowship in tumor immunology at the Brigham & Women’s Hospital and the Dana Farber Cancer Institute in Boston, Massachusetts. Silberman has played key roles in the development of many drugs, including Gleevec(TM), for which she led the global clinical development at Novartis. Silberman advanced several original, proprietary compounds into Phases I through III during her work with leading biopharmaceutical companies, including Bristol-Myers Squibb, AstraZeneca, Imclone and Roche.

CNS Pharmaceuticals Inc. (NASDAQ: CNSP), closed Monday’s trading session at $1.46, off by 5.8065%, on 121,936 volume. The average volume for the last 3 months is 121,801 and the stock's 52-week low/high is $1.38999998/$4.46000003.

Recent News

PlantX Life Inc. (CSE: VEGA) (Frankfurt: WNT1) (OTCQB: PLTXF)

The QualityStocks Daily Newsletter would like to spotlight PlantX Life Inc. (CSE: VEGA) (Frankfurt: WNT1) (OTCQB: PLTXF).

  • PlantX has made important moves recently, including additions to its Board of Directors, and the decision to commence an NCIB to repurchase up to 5% of its common shares
  • Going forward, the company plans to sustain its ongoing retail branding initiative-renaming existing brick-and-mortar stores as “XMarket”
  • Physical stores in British Columbia, Squamish, and Venice Beach, California, will be re-branded as XMarket
  • The XMarket Squamish store will host a grand opening event on October 14, 2021, while the Tel Aviv one is scheduled for opening on November 15, 2021

PlantX Life (CSE: VEGA) (Frankfurt: WNT1) (OTCQB: PLTXF) recently marked some significant milestones to improve its position for the remainder of the 2021 fiscal year. So far, the company has made key appointments to its Board of Directors and has also announced the intention to commence a normal course issuer bid (“NCIB”) to repurchase up to 5% of its common shares. PlantX Life (CSE: VEGA) (OTCQB: PLTXF) (Frankfurt: WNT1) today announced that it has launched as a seller on Walmart Marketplace in the United States. According to the update, PlantX will offer over 500 plant-based grocery items ranging from a variety of brands such as Oatly, Nature's Path, Made in Nature and Simply Organic on the U.S.-based Walmart Marketplace. To view the full press release, visit https://ibn.fm/6RJfz

PlantX Life Inc. (CSE: VEGA) (Frankfurt: WNT1) (OTCQB: PLTXF) aims to redefine the plant-based community through e-commerce, with a core objective of becoming the most trusted and convenient destination for people living plant-based lives. PlantX is a multifaceted marketplace providing consumers all things plant-based ranging from an efficient e-commerce experience, connecting consumers with interactive PlantX brick-and-mortar stores, and a PlantX home delivery system for products, meals, recipes and more.

PlantX is a high-growth technology company focusing on consumer-packaged goods (“CPG”) for the plant-based opportunity. The PlantX platform aims to serve as the digital face of this community with its one-stop-shop for everything plant-based, including:

  • An easy-to-use e-commerce shopping experience featuring the following:
    • Plant-based grocery items (from all your pantry needs to vitamins, cosmetics and even pet food)
    • Meal delivery with recipes created by well-known plant-based chefs throughout the world
    • Plant shop – delivering a wide variety of affordable indoor houseplants to homes across Canada and the U.S.
    • Easy to follow plant-based recipes every week
    • Partnerships with restaurants, nutritionists, chefs and brands
    • A community of like-minded individuals
  • State-of-the-art flagship PlantX locations

Since first launching in February 2020, PlantX Life has offered various services available through its comprehensive platform. This online marketplace features over 10,000 items across diverse product categories such as pantry items, beverages, personal care, pet food and indoor plants. In addition, PlantX has collaborated with renowned chefs and nutritionists to create 20 unique and pre-made meals delivered to the comfort of your own home.

Headquartered in Vancouver, Canada, PlantX’s mission is to spearhead the plant-based movement, celebrate and promote health and wellbeing, raise plant-based awareness in a hyper-palatable world, connect with global consumers and forge a welcoming plant-based community.

The company currently reports 4 million stock options and 24 million warrants outstanding, with a total of 88,832,159 shares issued and outstanding and a total market cap of $89.9 million on January 18, 2021. PlantX has continued to catalyze its capital markets dynamics by applying to list its common shares on the Nasdaq Capital Market (“NASDAQ”). The company’s common shares are eligible for electronic clearing and settlement through The Depository Trust Company (“DTC”) in the United States.

Market Outlook

With its comprehensive e-commerce platform, PlantX is strongly positioned for a prominent role in the fast-growing plant-based food market, e-commerce and the online food delivery sectors. The global plant-based food market is expected to reach $74.2 billion by 2027, expanding at a CAGR of 11.9%. Similarly, the online food delivery market has steadily grown, especially during the current pandemic. This trend seems here to stay. In the United States alone, the sector is expected to report $28.5 billion by 2024, with companies such as UberEats experiencing 152% increases in food deliveries in the summer of 2020.

Complementary to these trends, and as a result of the COVID-19 pandemic, online sales and digitization have also both grown exponentially in 2020. Grocery shopping has seen a remarkable transition to e-commerce, with online grocery sales growing by 53% in 2020. Amid the pandemic-imposed physical interactions and related consumer behavior change, large retailers have been compelled to meet this surge in e-commerce demand. For example, Whole Foods Markets has increased its online sales capacity by over 60% in 2020. The global meal kit delivery system is also becoming increasingly popular and is expected to achieve a market value of $19.92 billion by 2027, expanding at a CAGR of 12.8%.

PlantX aims to capitalize on this anticipated exponential market growth of the plant-based, e-commerce and home-delivery industries.

Digital Platform for the Plant-Based Community

The digital interface provided by PlantX spans a health and wellness initiative that offers thousands of plant-based products, meal delivery, indoor plants, recipes and a community space for those who are like-minded about plant-based products and healthy lifestyles. PlantX has been compared to Amazon, except with a focused tailored selection of plant-based offerings.

PlantX provides everything a consumer needs for plant-based living at the click of a button. With PlantX, customers can:

  • Shop
  • Find recipes
  • Read blogs
  • Join a community forum
  • Listen to podcasts
  • View cosmetics
  • Research vitamins
  • Purchase plant-based pet foods
  • Read corporate updates
  • Subscribe to an insightful newsletter

The company’s website was designed with a user-friendly interface that allows customers to visit the site and easily find what they need. Forums for communicating with a plant-based community make it easier to swap recipes or locate the best restaurants serving vegan and vegetarian-friendly cuisine.

PlantX Flagship Locations – British Columbia (Canada), San Diego (California), & the State of Israel

PlantX will link the e-commerce platform to flagship brick-and-mortar stores for a highly sensory customer experience. This is anticipated to drive corporate growth and global brand recognition.

These PlantX branded flagship locations will first launch in:

Customer engagement, education and creating a global plant-based community will be furthered through this initiative.

PlantX Restaurant Partnerships

With consumers becoming better informed and more health and environmentally conscious, a growing number of restaurants will start catering to the needs of customers who are vegan, vegetarian, have food-allergies (or specialized diets), or simply want to eat healthier.

PlantX proactively aims to support this change and help restaurants meet the needs of the plant-based community. Restaurants that want to increase revenue, drive traffic and make an impact can therefore partner with PlantX to better serve their customers by expanding and refining their menus.

Future Goals for PlantX Life

Having successfully completed all of the milestones that PlantX had set-out to achieve in the second half of 2020, PlantX strives to continue scaling through organic growth, strategic partnerships and accretive M&A opportunities. The upcoming plans from PlantX includes a global expansion strategy for distribution in North America, Europe and Israel.

Verticals launched in 2020 include:

  • New meals and programs by renowned chefs
  • Flagship PlantX locations
  • PlantX branded goods
  • United States meal delivery and LIV
  • Online peer-to-peer fitness

Management Team

Sean Dollinger, the Founder of PlantX Life Inc., has had a very active professional career that started when he was only 17. While still in college, he started a delivery service that soon became one of Canada’s largest delivery firms (before companies like Postmates and Uber Eats ever existed). In 2014, Mr. Dollinger founded Namaste Technologies, the largest international e-commerce distributor of vaporizers and accessories. He brought Namaste public and turned it into a $1.2 billion business in two years. After finding a plant-based diet himself, and seeing the massive benefits that it provided for him, he decided he wanted to find a way to give back to the community and focus on something he loves. PlantX Life was born from this desire and became his passion project. He truly walks the talk.

Julia Frank is the CEO of PlantX Life. She has an MBA in digital entrepreneurship, and, in her past roles, she set up renowned strategies for large corporations like BMW and Daimler in Germany. Beyond her professional business prowess, Ms. Frank finds tremendous joy in preparing delicious and nutritious plant-based meals and is the face of the company. She practices a healthy and active lifestyle that includes experiencing as many cultures as possible to add more knowledge of the industry at large. This globally inclusive perspective gives her the unique advantage of being able to see plant-based living from all angles.

Lorne Rapkin, CPA, CA, LPA, is the President and CFO of PlantX Life and is also a partner at Rapkin Wein LLP. He has experience with clients in almost every industry, including finance, professional services, real estate, automotive, media and manufacturing. Mr. Rapkin works very closely with investment and public firms, seeking to comply with IFRS accounting standards. His roles often require him to work with management on go-public transactions, acquisitions and mergers. His keen attention to detail is an asset to any client he works with, and PlantX is no exception.

Alex Hoffman is the company’s CMO and has spent the last 10 years in the creative field cultivating her passion for design and appreciation for beauty. This is apparent in all of the creative decisions and outcomes seen at PlantX. Her role within the company is to oversee all of the brand marketing activities, establish and execute key processes for rapid growth, and work closely with management to refine the brand’s message for key segments and emerging opportunities. She has a sharp vision for exactly what’s needed to convey the company’s core messages and principles to both the public and investors, and she is a visionary with respect to creative marketing ideas and concepts.

PlantX Life Inc. (CSE: VEGA) (Frankfurt: WNT1) (OTCQB: PLTXF), closed Monday’s trading session at $0.37, off by 6.965%, on 332,825 volume. The average volume for the last 3 months is 332,825 and the stock's 52-week low/high is $0.170000001/$1.85000002.

Recent News

DSG Global Inc. (OTCQB: DSGT)

The QualityStocks Daily Newsletter would like to spotlight DSG Global Inc. (DSGT).

  • DSG Global (OTCQB: DSGT), together with Imperium Motor Corp. (“IMC”), its automotive division and an electric vehicle (“EV”) sales and marketing company, is strengthening positioning in the growing market for smart new-energy vehicles. Focused on offering a wide variety of affordable vehicles equipped for the North American market with emphasis on great design, a green mindset and superior performance and functionality, IMC is working with two partners, Skywell Auto and Jonway Automotive Group, to offer 26 EV models for sale at both DSGT California facilities. To view the full article, visit https://ibn.fm/63R7E
  • Ever since President Joseph Biden assumed office, his administration has made it clear that electrifying America’s roads will be a top priority. Biden spent his first months in office working on and subsequently unveiling a gargantuan infrastructure bill that would invest billions of dollars into beefing up the country’s woefully inadequate electric vehicle (“EV”) public charging infrastructure. This was followed by a recent announcement by the White House stating that the government was looking to achieve 50% electric vehicle sales by 2030 in a bid to meet emission standards. Such federal government initiatives add ballast to the work of electric vehicle sector players such as DSG Global Inc. (OTCQB: DSGT), which would encourage as many motorists as possible to switch to EVs.

DSG Global Inc. (OTCQB: DSGT) is an emerging global technology company with interconnecting businesses in fast growing market sectors. With roots in the golf industry, the company specializes in golf fleet management and is moving quickly into road-ready electric vehicles for delivery in the third quarter of 2021.

In 2019, the company secured exclusive North America distribution rights for Jonway Automobile Co. road-ready electric vehicles (EVs). Jonway, based in Zhejiang, China, began manufacturing new vehicles s in 2003 and today produces Electric powered Cars, Trucks, Vans, SUV’s, and Scooters. Jonway vehicles are exported to more than 80 countries and are built to comply with U.S. safety and environmental standards.

These vehicles are being sold via DSG’s wholly owned subsidiary, Imperium Motor Company (IMC). The move into consumer vehicles capitalizes on the company’s strength in the selection and distribution of EVs, the ability to work with large manufacturers and in application of proprietary technology unique to DSG. DSG’s advanced fleet tracking can be integrated into Jonway EVs to offer a customized scalable and integrated solution to meet the needs of small businesses and large enterprises.

The Future is Electric

With decades of EV experience in golf, including distribution of highly advanced carts, DSG recognized the huge chasm between consumer interest in acquiring road ready EVs versus current EV models’ lack of availability and affordability. As such, the company focused on becoming a distribution and EV brand management company unencumbered by the manufacturing process. The manufacturers take responsibility for building vehicles to DSG’s specifications and fulfillment of regulatory and licensing requirements.

DSG has also established a distribution agreement with Skywell New Energy Automobile Group Ltd., an Asian-based EV manufacturer. Skywell will supply DSG with SUV’s, Passenger Vans, Cargo Vans, Commercial Vehicles and Buses that will be fully certified for use in the United States.

Brands

Imperium Motor Company (IMC) seeks to transform the way the world drives by making greener transportation available to everyone. IMC is an EV sales and marketing company that distributes directly to consumers and through third party distributors, offering a wide variety of affordable vehicles equipped for the North American market. The company’s emphasis is on great design, a green mindset, performance and functionality. Its vehicles include 26 models of high-speed, mid-speed and low-speed electric vehicles including cars, trucks, SUVs, vans, buses and scooters.

Vantage Tag Systems (VTS) is a global leader in the design, manufacture, and marketing of fleet management solutions for the golf industry. VTS has developed the TAG suite of products that represents the industry’s first completely modular fleet management solution. The company’s patented analytics, mobile touch screen GPS units and electric golf carts are sold around the world through a network of established distributors and partnerships with notable brands in fleet and equipment manufacture. VTS solutions also have applications in managing commercial, agricultural, military and government fleets. VTS is a wholly owned subsidiary of DSG Global.

Market Outlook

The global EV market was valued at $273 billion in 2017, according to Fortune Business Insights, and is projected to exceed $987 billion by 2027, with a projected CAGR of 17.4 percent. The relative high manufacturing costs of EVs compared to gasoline-powered vehicles and the resulting higher sticker price to consumers are major obstacles to near term market adoption.

The global e-bike market is estimated to grow to $70 billion by 2027 from its current valuation of $41.1 billion. An estimated 130 million e-bikes are expected to be sold globally over the next two years. The U.S. imported approximately 600,000 e-bikes in 2020, according to the Light Electric Vehicle Association, and its analysts expect that number will grow substantially in 2021.

Management Team

Robert “Bob” Silzer is the CEO of DSG Global. He is a serial entrepreneur who turns technology ideas in high growth industries into profitable businesses. With roots in the golf industry, he founded Vantage Tag Systems in 2008. Vantage Tag Systems is now a DSG subsidiary specializing in GPS-enabled fleet management.

Zahir Loaiza is the interim CFO of DSG Global. She assumed the role in March 2021, after having previously served as the company’s Corporate Controller. Her diverse international experience includes working at a publicly traded mining company, several law firms and more in the U.S., Canada and South America. Prior to pursuing a career in corporate finance, she was the owner of two retail entities.

Rick Curtis is the president and COO of Imperium Motor Company, the automotive subsidiary of DSG Global. His 40-year background in the automotive industry includes manufacturing, vehicle distribution, parts distribution, service management, dealer development and executive management of dealer groups. Prior to joining Imperium, Mr. Curtis served as president of Mullen Technologies and grew the company into a world class provider of electric vehicles, battery technology and energy storage systems.

William “Bill” Rex is president of Imperium Motor’s EV Bus and Motor Home Division. He has more than 40 years’ experience at suppliers of buses/electric buses, motor homes, trucks, specialty vehicles and batteries. He is the founder of Rexhall Industries Inc., formerly a publicly traded manufacturer of RVs and distributor of buses and coaches. He previously served as president of THOR West, a subsidiary of THOR Industries that manufactures shuttle buses, and as president of BYD Coach and Bus.

Patrick J. Parenti is the SVP Global Sales at DSG subsidiary Vantage Tag Systems. He has nearly 30 years of experience in golf and golf course management. Prior to joining DSG in 2012, Mr. Parenti served for 10 years as SVP at ProLink Systems, a leading global provider of GPS golf-course management systems.

Clint Singer is Director of Engineering at Vantage Tag Systems. He has been a senior developer in the golf industry for more than 20 years and has an extensive background in GPS systems.

Daniel Price is Technical Operations Manager of DSG Global’s European Region, UK, South Africa. In addition to his background in mechanical and electronic engineering, he is an audio engineer, specializing in automotive audio and security. He has also worked with high end electronic security companies in the UK and previously owned an electronic security and CCTV company.

Steven Mueller is Operations Manager at Vantage Tag Systems. He worked in the global pulp and paper market for nine years, facilitating the global movement of thousands of tons of timber products annually. Additionally, he has a successful decades-long track record of managing operations and consulting for a wide range of retail businesses.

DSG Global Inc. (DSGT), closed Monday’s trading session at $0.27, off by 6.6471%, on 1,034,690 volume. The average volume for the last 3 months is 1.035M and the stock's 52-week low/high is $0.037999998/$1.51999998.

Recent News

Delic Holdings Inc. (CSE: DELC) (OTCQB: DELCF)

The QualityStocks Daily Newsletter would like to spotlight Delic Holdings Inc. (CSE: DELC) (OTCQB: DELCF).

Delic Holdings (CSE: DELC) (OTCQB: DELCF), the leading psychedelic wellness platform, has announced plans to merge with Ketamine Wellness Centers Arizona LLC (“KWC”), which would create the largest psychedelic wellness chain in the country. The binding merger agreement would create 12 open locations — 10 KWC locations and two Delic locations — with plans in place to open 15 additional clinics in the next 18 months. KWC’s ketamine infusion treatment clinics are located in Arizona, Colorado, Florida, Illinois, Minnesota, Nevada, Texas and Washington; Delic’s clinics are in California and Arizona. To view the full press release, visit https://ibn.fm/5zfmW

Delic Holdings Inc. (CSE: DELC) (OTCQB: DELCF) is the leading psychedelic wellness platform, committed to bringing science-backed benefits to all and reframing the psychedelic conversation. The company owns and operates an umbrella of related businesses, including trusted media and e-commerce platforms like Reality Sandwich and Delic Radio; Delic Labs, the only licensed entity by Health Canada to exclusively focus on research and development of psilocybin vaporization technology; Meet Delic, the premiere psychedelic wellness event; and Ketamine Infusion Centers, one of the largest ketamine clinics in the country.

Delic is backed by a team of industry and cannabis veterans and a diverse network, whose mission is to provide education, research, high-quality products, and treatment options to the masses. Its founders helped build the multi-billion-dollar cannabis industry and aim to do the same in psychedelics as it follows a similar path toward legalization. In its quest to advance the new psychedelic renaissance upon us, Delic has become the pioneer in its field, creating an ecosystem of opportunities by investing in cutting-edge ideas.

The Vancouver-based company was formed in 2019 to address the growing interest in psychedelic wellness backed by science. Delic was the ‎first psychedelic umbrella platform. It is currently a trusted source for those interested in ‎psychedelic culture, education, treatments, and more.

While other emerging companies focus on patent medicine and big pharma for substances limited by government regulation, Delic is blazing a unique trail. It identifies ancillary and fully legal opportunities like IP, new media, live events, ketamine clinics (with the ability to offer additional psychedelic treatments once legalized, and large-scale production and brings them under its big tent of resources and reach.

The Big Problems Delic Is Addressing

  • Fifty percent of Americans will meet the criteria for a mental health condition sometime in their lifetime. The FDA has approved psilocybin therapy as a breakthrough therapy for depression.
  • Every 40 seconds, someone in the world commits suicide. Ketamine has been shown to decrease thoughts of suicide significantly. In 2019, the FDA approved esketamine as a fast-acting antidepressant.
  • Traditional palliative care methods do not eradicate end-of-life (EOL) anxiety. LSD and psilocybin have been shown to reduce EOL anxiety for terminally ill patients. Eighty percent of terminally ill patients with psilocybin sessions experienced significant reductions in depression and anxiety.
  • Approximately 50 million people in the U.S. are addicted to some tobacco product. Research shows that psilocybin is helping people quit smoking.

The Delic Ecosystem

The Delic Ecosystem covers three main areas: media, health, and science. The media focus is educating and motivating the masses through a variety of digital platforms, like Delic’s Reality Sandwich digital magazine, a free public education platform providing psychedelic guides, news and ‎culture (1.4+ million page views in 2020 and 54k social media followers across all platforms); Meet Delic, the first-ever psychedelic wellness summit and the premier psychedelic wellness event based in Las Vegas (over 2,000 live attendees and 5,000+ email subscribers); and Delic Radio (over 43 episodes and 100k total streams). Delic has also been featured in numerous media outlets like Forbes, NBC News, The Joe Rogan Experience, Daily Beast, High Times, and The Dr. Drew Podcast.

The focus of Delic’s health operations is the most accessible psychedelic treatments that can help billions of people live happier lives. Delic does this through one of the largest ketamine clinic chains in the country, Ketamine Infusion Centers (KICs), a limited liability corporation formed under the laws of Arizona that runs three ketamine clinics located in Bakersfield, California, and Phoenix, Arizona. Its management team has over 15 years of experience in the clinic and medical space, scaling and operating over 20 clinics, with a plan to open 10 more clinics in the next 18 months. Together, these clinics have overseen 4,000+ treatments delivered to date.

The focus of Delic’s science operations is developing IP and advanced extraction and testing facilities that are the backbone of the legal market. Delic carries this out through Delic Labs, a licensed cannabis and psilocybin research laboratory based in Vancouver. It’s the only entity licensed by Health Canada to exclusively focus on research and development of psilocybin vaporization technology.

Founded by award-winning chemists, Delic Labs focuses on extraction optimization, analytical testing, and chemical process development to advance the cannabis and psilocybin industries. Health Canada gave it a Section 56 Exemption to work with psilocybin compounds, allowing the company to possess and research these products for development and quality control before they hit the market.

Latest Acquisition – Homestead Book Company

On March 4, 2021, Delic announced its acquisition of Seattle-based Homestead Book Company. Homestead is a legacy counterculture distributor of psychedelic media. It’s also the creator of one of the first self-contained psilocybin mushroom grow kits.

The acquisition of Homestead is an exciting one, as it shows how Delic is increasing accessibility to this nascent industry within regulated jurisdictions. Homestead has sold tens of thousands of mushroom kits globally and was one of the earliest distributors for High Times and many other counterculture publications.

The Homestead acquisition allows Delic to increase its product offerings on its website, Reality Sandwich, which recently hit a record for average monthly traffic of over 200,000 unique visitors and over 2.6 million active readers in 2020.

Market Outlook

The psychedelic renaissance is here. Just in time to help address the global mental health crises, plant medicines have the potential to help billions of people live happier lives. Thanks to university-led and FDA-approved studies, North America is leading the way in advancing an industry as psychedelics are becoming accepted globally for therapeutic, medical, and recreational use. Here are some statistics:

  • 32 million people in the U.S. have used psychedelics at least once
  • 17% of all American adults between 21 and 64 have used psychedelics at least once
  • $500 billion is spent in the U.S. every year on prescription drugs
  • $238 billion is spent in the U.S. every year on mental health treatments and ancillary services
  • The anxiety disorder and depression treatment market is estimated at $16 billion
  • $187.8 billion was spent in 2013 on mental health and substance abuse disorders

Management Team

Delic Co-Founder and CCO Jackee Stang was an executive at High Times, a leading counterculture publication that became the voice for the cannabis industry. The monthly magazine had a circulation of over 500,000 copies per issue. Its website attracted 500,000 to five million users each month by 2014.

Likewise, company Co-Founder and CEO Matt Stang was a previous owner and operator of High Times, a position from which he played an instrumental in legalizing cannabis in multiple states and launched the Cannabis Cup in America. After interacting with the cannabis community for two decades, he helped found Delic in 2019 as one of the first psychedelic corporations. He shapes the company’s vision and path using his expertise in branding, marketing, business development, and product viability.

Delic’s VP of Business Development, John Coleman, Ph.D., is a former president of Anandia Labs, a biotech company focused on genetics and analytics. Having experience in both science and business, Dr. Coleman is well-equipped to lead Delic’s business development efforts as it strives to enter new vertical markets.

Zak Garcia is the company’s Chief Marketing Officer. He was the former CMO of Bulletproof Inc., maker of the well-known Bulletproof Coffee brand. Mr. Garcia is a marketing and leadership strategist who helped grow Bulletproof Coffee to over $250 million in revenue.

Delic Holdings Inc. (DELCF), closed Monday’s trading session at $0.25, off by 7.1667%, on 249,412 volume. The average volume for the last 3 months is 249,412 and the stock's 52-week low/high is $0.170000001/$1.03799998.

Recent News

Avricore Health Inc. (TSX.V: AVCR) (OTCQB: AVCRF)

The QualityStocks Daily Newsletter would like to spotlight Avricore Health Inc. (OTCQB: AVCRF).

  • Health diagnostics technology innovator Avricore Health has introduced its HealthTab platform as a means of improving patients’ ability to monitor their health conditions through point-of-care testing under the guidance of trained pharmacists
  • HealthTab uses partnerships with molecular testing device makers to establish rapid molecular testing services in pharmacies, including the Shoppers Drug Mart pharmacy network in Ontario
  • The initial rollout has taken place in 15 Shoppers pharmacies, with rapid scaling planned to achieve more than 600 locations by the end of 2023
  • HealthTab’s diagnostics platform is designed to be high quality with appropriate approvals and certifications, helping patients to avoid delays in lab result turnaround
  • The COVID pandemic has exposed weaknesses in lab result turnaround time capacity, but Avricore’s testing offers solutions that include COVID infection analysis under a new agreement

The unexpected advent of the COVID-19 global pandemic last year taxed health response infrastructures on numerous fronts as the rapidly spreading SARS-COV-2 virus caused an influx of sick and dying patients at hospitals struggling to keep up with demands for intensive care. Pharmacy services developer Avricore Health (TSX.V: AVCR) (OTCQB: AVCRF) is helping to tackle the problem head-on with the rollout of its Point of Care Testing ecosystem that encourages patients to get lab-quality results for COVID and other illnesses at local pharmacies, with the results then shared seamlessly to patients, medical professionals and researchers in real time without compromising health privacy. 

Avricore Health Inc. (TSX.V: AVCR) (OTCQB: AVCRF) is a pharmacy service innovator focused on acquiring and developing early-stage technologies aimed at moving pharmacy forward. Through its flagship offering, HealthTab™ (a wholly owned subsidiary), the company aims to make actionable health information more accessible to everyone by creating the world’s largest network of rapid testing devices in community pharmacies.

HealthTab

HealthTab is a turnkey point-of-care testing solution that effectively turns pharmacies into diagnostic hubs (sometimes known as ‘Community Diagnostic Centers’, or CDCs) and connects them on a single, cloud-based platform.

The HealthTab network model is unlike anything in pharmacy today. It gives knowledgeable and trusted pharmacists a greater role in primary care delivery and empowers patients to take more control of their health. It also reduces costs and waiting times while providing many potential revenue streams, including equipment leasing & consumables, direct access testing, disease prevention & management programs, sponsored health programs, decentralized clinical trials, real world data (RWD) sets and third-party app integration through API.

Agreement with Shoppers Drug Mart

In June 2021, Avricore signed a Master Agreement with select Shoppers Drug Mart pharmacies to pilot the HealthTab platform. This agreement gives patients access to point-of-care blood screening and health-data management for potential risks relating to diabetes and cardiovascular conditions using HealthTab-integrated Afinion 2™ analyzers provided by Abbott Rapid Diagnostics.

Avricore is the first pharmacy solutions provider to partner with Abbott (NYSE: ABT), the global health care company and diagnostics leader in Canada. In May 2021, the company signed a supplier distribution agreement to expand the distribution of Abbott’s Afinion 2 and associated tests for diabetes and heart disease screening in community pharmacies in Canada. This agreement includes valuable HbA1c testing, a critical marker for the screening and management of diabetes.

Near Term Goals

Near term goals for Avricore include expansion into more pharmacies across Canada, followed soon after by entering the U.S. and UK markets. The company has made significant strides in testing and developing its technology and is moving into the commercialization stage.

Strategic partnerships like those with Abbott and select Shoppers Drug Mart pharmacies advance Avricore closer to becoming an incredibly dominant player in the community diagnostics space. The company aims to make actionable health information more accessible for everyone by creating the world’s largest rapid testing network in pharmacies.

Market Outlook

In 2020, the global point-of-care testing (POCT) market was valued at $34.49 billion and expected to expand at a compound annual growth rate (CAGR) of 9.4 percent to reach a projected $81.37 billion by 2028. This upsurge is expected to be driven largely by increased demand for screening and management tools for chronic diseases, as well as rapidly assessing infectious diseases such as COVID-19.

The accessibility of POCT has been an increasing priority of the world’s leading health organizations and experts. Pharmacies are ideal ‘hubs’ within the community to offer patients better access to the numbers they need to know for preventing or treating conditions such as diabetes and heart disease or the timely diagnosis of infection.

Management Team

Avricore’s leadership team brings a diverse portfolio of expertise across the health care and biotech industries, as well as technology, finance and communications. Together, they share a common vision of moving pharmacy forward and have positioned the company for significant future growth and expansion.

Hector Bremner is the CEO of Avricore. He has over 15 years of senior and executive experience across various industries, including international trade, natural gas, marketing and communications. He owned and operated TOUCH Marketing, a boutique marketing and communications firm based in Vancouver, from 2007 to 2013. Mr. Bremner has also served as the executive assistant to the Deputy Premier and Minister of Natural Gas Development, Responsible for Housing, as well as the Minister of International Trade and Minister of Small Business. In 2015, he joined Vancouver’s Pace Group Communications as VP of Public Affairs.

David Hall is the Chairman and a Director of Avricore. His leadership spans five different companies. He is currently the Chairman of RepliCel Life Sciences and a member of the boards of TrichoScience Innovations, AdvantageBC and Providence Health Care Research Institute. Mr. Hall also served as Chairman of Perceptronix Medical Inc.; Chief Financial Officer, Secretary & Treasurer of Angiotech Pharmaceuticals Inc.; President & Director at Newcastle Resources Ltd.; and Chairman for LifeSciences British Columbia.

Kiki Smith is Avricore’s CFO. She has over 20 years of experience assisting private and public companies in the roles of accountant, corporate controller and CFO in mining, oil & gas, real estate, high technology, food production and investment fund management. She currently provides consulting services in M&A, financial reporting and regulatory compliance to several public and private companies across several investment sectors. Ms. Smith is a member of the Chartered Professional Accountants of British Columbia and has a bachelor’s degree in economics from the University of British Columbia.

Rodger Seccombe is the Head of Avricore’s HealthTab division and the co-founder and former CEO of HealthTab Inc. Mr. Seccombe has over 20 years of experience launching and running companies in software, health care technology and clean energy. He is a recognized industry expert in direct-to-consumer and point-of-care testing technology. In 2006, he joined the start-up team at Canadian Bioenergy Corporation and helped pioneer the development of the renewable fuel industry in Canada. Before HealthTab, he designed and developed cloud-based informatics systems currently in use by some of the world’s leading medical laboratories and instrument manufacturers.

Avricore Health Inc. (OTCQB: AVCRF), closed Monday’s trading session at $0.125135, off by 13.4134%, on 2,900 volume. The average volume for the last 3 months is 2,900 and the stock's 52-week low/high is $0.032999999/$0.485619992.

Recent News

Moon Equity Holdings Corp. (OTC: MONI)

The QualityStocks Daily Newsletter would like to spotlight Moon Equity Holdings Corp. (MONI).

  • MONI is an investment company focusing on acquisitions in the fintech, crypto, precious metals, and real estate sectors
  • MONI reveals its participation in the annual SALT Conference, one of the world's premier hedge fund events held in New York between September 13-15, 2021
  • In addition to their marketing efforts, MONI is actively expanding their business – including the acquisition of mining company, Royal Costino LLC, and the development of their cryptocurrency business

Moon Equity Holdings (OTC: MONI) is an investment company focusing on acquisitions in fintech, crypto, precious metals, and real estate sectors. The company has centered its business philosophy around providing shareholders with a well-diversified acquisition portfolio focused on income-generating strategies that produce long-term gains.

Moon Equity Holdings Corp. (OTC: MONI) is an investment company that focuses on acquisitions in the fintech, crypto, precious metals and real estate sectors. The company’s goal is to enhance the profitability of these acquired companies, which in turn will increase shareholder value. Moon Equity Holdings’ philosophy is to provide its shareholders with a well-diversified acquisition portfolio focused on income-generating strategies that produce long term gains.

The company has been working on a crypto component in development, along with two trademarked products that will revolutionize how people gift and purchase cryptocurrency. With this, Moon Equity Holdings will use decentralized technology to enhance customer experience. First-rate service is the cornerstone of Moon Equity Holdings’ success. The company’s focus on best-in-class customer service is expected to create a loyal brand following and generate repeat business.

Business Operations

Moon Equity Holdings Corp. acquired Royal Costino LLC as a wholly owned subsidiary for its newly created Mining Division. Its primary business is processing, buying, selling and exporting precious metals. This acquisition completes the first step of the two planned mining acquisitions for this year. The acquisition is expected to significantly enhance revenue for the company, generating an estimated $2 million per month in additional income. Royal Costino’s facility has been in operation since 2013, and its team has more than 30 years of experience in this field.

Management Team

Moon Equity Holdings Corp. has assembled a highly skilled and experienced management team.

Alison Galardi is the CEO of Moon Equity Holdings Corp. Before joining the company, she gained more than 20 years of experience at Fortune 100 financial services companies, including Spear Leeds & Kellogg, TIAA-CREF and Citigroup, where she held positions in global banking, institutional sales, trading and investor relations.

Anthony Cappaze is head of Moon Equity Holdings’ Mining Division with more than 30 years of mining experience. He was founder and CEO of Royal Sovereign Costino prior to its acquisition by Moon Equity Holdings Corp.

Advisory Board

Sue Ferrari is a Senior Industry Principal that has over 20 years of experience in innovation, insights and analytics across technology, financial services and media, including VP, Bank of NY Mellon and ADP.

Maureen Vizvary worked at Microsoft, HP and Xerox launching innovative products and developing marketing campaigns that rebrand entire organizations. During her tenure at Microsoft, she served on the advisory team restructuring Microsoft’s mid-market sales division and developed award-winning, cutting-edge technology to transform the way hospitals interact with patient information.

Colleen Cline has over 33 years’ experience in the financial services and insurance industries, including sales, marketing, business development and management. She worked with Fifth Third Bancorp and Allstate Insurance, receiving various industry awards in sales, marketing and customer satisfaction. She is also an entrepreneur and top performer in the health care and wellness industry.

Moon Equity Holdings Corp. (OTC: MONI), closed Monday’s trading session at $0.0594, off by 8.6154%, on 1,902,416 volume. The average volume for the last 3 months is 1.892M and the stock's 52-week low/high is $0.0003/$0.146540001.

Recent News

InnerScope Hearing Technologies Inc. (OTC: INND)

The QualityStocks Daily Newsletter would like to spotlight InnerScope Hearing Technologies Inc. (INND).

InnerScope Hearing Technologies (OTC: INND), an emerging and disruptive leader in the direct-to-consumer hearing-health technology space, will be a featured participant in this month’s virtual Home Health & Diabetes Care Program. The three-day event is scheduled for Sept. 20–23, 2021, with InnerScope’s online presentation focused on its Bluetooth app-controlled self-adjusting hearing aids, Bluetooth app-controlled self-adjusting personal sound amplifiers products, doctor-formulated dietary hearing and tinnitus supplements, and other ear and hearing health-related products. INND will be the only company during the conference representing and presenting the hearing device and hearing healthcare category. To view the full press release, visit https://ibn.fm/OumDg

InnerScope Hearing Technologies Inc. (OTC: INND) is a Nevada corporation incorporated on June 15, 2012, with its principal place of business in Roseville, California. The company was initially started in 2006 – operating as InnerScope Advertising Agency Inc. – to provide advertising and marketing services to retail establishments in the hearing device industry. On August 25, 2017, the company changed its name to InnerScope Hearing Technologies Inc. to better reflect its current direction as a hearing health technology company that manufactures, develops, distributes and sells numerous innovative hearing health-related products, hearing treatments and hearing solutions, direct-to-consumer (DTC) through a scalable business model.

The company is a manufacturer and a distributor/retailer of DTC, FDA (U.S. Food and Drug Administration) registered, Bluetooth app-controlled hearing aids and personal sound amplifier products (PSAPs), hearing-related treatment therapies, doctor-formulated dietary hearing supplements, proprietary CDB oil for treating tinnitus and assorted hearing and health-related products targeting approximately 70 million Americans suffering from hearing-related problems. The company’s mission is to improve the quality of life of the 70 million people in North America and the 1.5 billion people worldwide who suffer from hearing impairment and/or hearing-related issues.

The management team of InnerScope is applying decades of industry experience and believes it is well-positioned, with its innovative in-store point-of-sale Free Self-Check Hearing Screening Kiosks (“Hearing Kiosks”), to directly benefit when the Over the Counter (OTC) Hearing Aid Act (the “OTC Hearing Aid Law”) is enacted (expected in late 2021 based on the President’s Executive Order issued on July 9, 2021) The OTC Hearing Aid Law allows OTC hearing aids for perceived mild-to-moderate hearing losses to be sold in retail stores without having to see a professional. InnerScope’s Hearing Kiosk is designed to help the tens of millions of Americans with undetected/untreated mild-to-moderate hearing loss treat themselves with the company’s easy, convenient and affordable OTC hearing aids, in-store and/or online.

Industry Game-Changer – New Emerging Market with 48 Million Potential Customers

The following is sourced from The White House Fact Sheet detailing an Executive Order from President Biden aimed at saving Americans with hearing loss thousands of dollars by allowing hearing aids to be sold over the counter at drug stores:

“Hearing Aids: Hearing aids are so expensive that only 14% of the approximately 48 million Americans with hearing loss use them. On average, they cost more than $5,000 per pair, and those costs are often not covered by health insurance. A major driver of the expense is that consumers must get them from a doctor or a specialist, even though experts agree that medical evaluation is not necessary. Rather, this requirement serves only as red tape and a barrier to more companies selling hearing aids. The four largest hearing aid manufacturers now control 84% of the market.”

On July 9, 2021, President Biden noted the following in reference to his Executive Order relating to hearing aids:

“Right now, if you need a hearing aid, you can’t just walk into a pharmacy and pick one up over the counter. You have to get it from a doctor or a specialist. Not only does that make getting hearing aids inconvenient, it makes them considerably more expensive, and it makes it harder for new companies to compete, innovate and sell hearing aids at lower prices.”

“As a result, a pair of hearing aids can cost thousands of dollars. That’s a big reason why just one in seven Americans with hearing loss actually use a hearing aid.”

InnerScope Game-Changers

For InnerScope, this Executive Order could present a significant opportunity. The company is uniquely positioned with a number of strategic advantages and offerings in the space, including:

  • First to Market: Free self-check hearing screening kiosks deployed in national pharmacy chains, big-box retailers & national and local groceries chains
  • Online Hearing Screening Tests: For national retailers to use their websites to attract more customers in conjunction with the company’s in-store hearing kiosks
  • The HearIQ App for iOS and Android users: Offers a free self-check hearing test and provides a user control function for InnerScope’s Bluetooth app-controlled self-adjusting rechargeable hearing devices
  • Customer Monthly Subscription Model: Offering the lowest, most affordable monthly payment options (as low as $42 per month for pair of rechargeable, app-controlled hearing aids) for consumers to purchase hearing aids and receive free upgrades every two years.

The In-Store Hearing Screening Kiosks and Online Free Hearing Screening Tests

Innerscope’s hearing screening kiosk and online hearing screening tests offer free self-check hearing evaluation using the world’s first “Hearing Triage” artificial intelligent pattern recognition software, which has a unique ability to classify both level (degree of loss) and pattern (type of loss). In addition, the software can detect the probable location of the hearing problem and its degree of severity.

The tests are developed as a hearing wellness tool to help track hearing ability and (if tests results indicate a hearing loss) make recommendations for in-store point of sale or online purchase of one of InnerScope’s hearing devices, as well as providing recommendations to see one of the professionals in InnerScope’s local contracted network of hearing health care experts for further follow-up testing if necessary. The software also generates an audiometric report which is instantly emailed to the customer.

The HearIQ App

InnerScope is the creator of the HearIQ App, which offers free self-check hearing tests and provides a user control function for InnerScope’s line of Bluetooth app-controlled self-adjusting rechargeable hearing devices. InnerScope developed the free hearing test part of the HearIQ App to help with the early detection of hearing loss for the 1.5 billion people worldwide who have untreated hearing loss or some form of hearing issues that may be undetected and do not have access to a computer for InnerScope’s online hearing screening test.

Hearing Aid Products

Through its dedicated online store, MyHearIQ.com, InnerScope offers affordable, direct-to-consumer, Bluetooth app-controlled, self-adjusting hearing technology to empower consumers to take control of their hearing care. InnerScope’s hearing technology allows the customer in less than 10 minutes using any smartphone to personalize each hearing device to their hearing needs using an onboard in-ear custom-fit self-testing feature through the HearIQ App.

InnerScope is shifting hearing health care from traditional brick-and-mortar hearing care clinics to customers’ homes by providing a unique solution to give customers top quality, affordable access to hearing aids without the need to see a hearing professional or go to a hearing care clinic. As a result, InnerScope can deliver the same level and quality of hearing technology and expert support for the customer from their homes at a fraction of the cost of traditional channels. All InnerScope hearing aid devices are medical-grade and available with professional remote programming and support services from one of the company’s licensed hearing professionals through the HearIQ App.

Hearing & Tinnitus Dietary Supplements

InnerScope has developed a proprietary line of doctor-designed hearing & tinnitus dietary supplements to help people with hearing problems protect themselves from future hearing issues. There are currently three types of formulas to choose from, including Ear-Ring Relief for the 60 million Americans who suffer from tinnitus, HearingVite + Memory Boost for people with hearing loss and cognitive issues, and HearingVite + Multivitamin for maintaining proper hearing health and levels of nutrients.

Complete Line of Hearing Health Care Products

InnerScope offers a brand label of assorted ear care and hearing aid maintenance products. In support of overall ear health and ensuring maximum performance from its hearing aids and comfort for its customers, InnerScope provides a whole line of care items, including cleaning kits, wipes, spray and drying tablets, ear cleaner for wax removal, a natural lubricant agent for new hearing aids and hydrating lubricating ear gel.

Verified Wholesale and Direct-to-Consumer Sales

InnerScope is a verified wholesaler with Walmart for premium affordable direct-to-consumer hearing aids, personal sound amplification and hearing health accessories. InnerScope also created an easy shopping experience for its hearing and tinnitus vitamins through Walmart and Amazon Prime. With new partnerships in the works, the company aims to add other online and brick-and-mortar establishments to its vitamin distribution network in the future.

Hearing Aid Market Outlook

The global hearing aid market is expected to reach $11.02 billion by 2028, growing at a CAGR of 7.4% during the forecast period. This marks a significant increase from the $6.47 billion value reported in 2020, an increase largely driven by innovations being made in hearing aid technology (https://ibn.fm/bRWUb).

As a leading wholesale provider and direct-to-consumer business, InnerScope is positioned to disrupt the global hearing aid market. Its partnerships with some of the United States’ largest retail distributors and wholesalers are only strengthening the company’s position within the industry.

Management Team

Matthew Moore is the President and CEO of InnerScope Hearing Technologies Inc. He grew up in the hearing health industry, working alongside his grandfather through internships and mentorships. At the age of 10 years old, he became Chief Marketing Officer and Chief Operating Officer of his parent’s private hearing aid practice, the largest in Northern California and the second largest in the state. Matthew has shown his leadership ability by creating distribution partnerships with big industry names and independent retailers/pharmacies.

Kim Moore is the Chief Financial Officer of InnerScope Hearing Technologies Inc. She has worked in the hearing aid industry for over 45 years, helping her father maintain his hearing aid practice in Central Valley, California. She began working on marketing with her father at the age of eight, learning that no customer walks through the door without proper advertising and marketing. As a licensed hearing instrument specialist, Kim has given hearing tests to more than 30,000 people.

Mark Moore is the Chairman and Co-Founder of InnerScope Hearing Technologies Inc. He has over 35 years of experience in hearing aid dispensing, practice management, private label brand management and hearing aid marketing. He has personally fit hearing aids to over 10,000 hearing-impaired people. In addition, he has been responsible for developing and testing proven new industry marketing and advertising methods and best practice strategies, which has made him one of the most sought-after experts in the hearing aid industry. Mark was previously a columnist for Advanced for Audiologists, a global industry publication, and served on the American Academy of Audiology (AAA) advisory board for AudiologyNow conventions. He has also developed patented and patent-pending nutritional supplements for hearing-related issues, aural rehabilitation programs and low-level laser therapy for tinnitus and sensorineural hearing loss.

InnerScope Hearing Technologies Inc. (INND), closed Monday’s trading session at $0.0094, off by 5.5276%, on 36,468,750 volume. The average volume for the last 3 months is 36.469M and the stock's 52-week low/high is $0.000000999/$0.097999997.

Recent News

Sugarmade, Inc. (OTC: SGMD)

The QualityStocks Daily Newsletter would like to spotlight Sugarmade, Inc. (OTC: SGMD).

  • States that have already legalized cannabis are seeing a spike in business thanks to the overwhelming convenience of cannabis delivery
  • Article reports that delivery services can “help surge revenue for retailers that jump in to take advantage”
  • Earlier this year, SGMD launched a new business initiative for the licensed delivery of cannabis products

According to a recent article, states that have already legalized cannabis, such as California, are seeing a spike in business thanks to the overwhelming convenience of cannabis delivery (https://cnw.fm/SrPtT). This is great news for Sugarmade (OTC: SGMD), an innovator in the dynamic California cannabis scene with majority control and ownership of cannabis delivery service Nug Avenue, based in Southern California and providing hand-selected top-shelf products from Stiiizy, Kanha, PlugPlay, Cookies and more.

Sugarmade, Inc. (OTC: SGMD) is a product and brand marketing company investing in operations and technologies with disruptive potential. The company is focused on collaborating with real people in real-time to identify the emerging desires and behaviors poised to unlock new opportunities and pathways for growth. Sugarmade seeks to redefine the marketplace by nurturing an innovative and compelling relationship between brand, botany and business – resulting in both undeniable consumer value and an intriguing cross-pollination of revenue sources.

The company’s core strategic plan is centered on expanding its end-market access as a central player in the growing California cannabis delivery marketplace while developing its in-house cannabis production capacity to verticalize operations in the space. Through a combination of organic growth and strategic acquisitions, Sugarmade intends to develop a full farm-to-door vertically integrated cannabis business.

Brand Portfolio

Sugarmade has investments in a number of subsidiaries with active operations in the California cannabis sector. These include:

  • NUG Avenue – Sugarmade owns a 70% stake in NUG Avenue, a cannabis delivery service based in Southern California providing hand-selected top-shelf products from Stiiizy, Kanha, PlugPlay and more.
  • BudCars – Sugarmade is an investor in cannabis delivery service of BudCars’ first operating location in Sacramento, California. BudCars is an online-shopping experience designed to provide new customers with an easy way to discover and order cannabis products within minutes.

Acquisition of Lemon Glow Company

On May 17, 2021, Sugarmade took a major step toward closing the loop on what its management team believes to be one of the most promising vertically integrated cannabis models in the thriving California market when it announced the signing of a definitive agreement for its acquisition of Lemon Glow Company Inc.

The Lemon Glow acquisition includes 640 acres of property, 32 of which have already been designated for outdoor cannabis cultivation. Per the company’s news release, the annual potential cultivation yield at the property is estimated to be approximately 4,000 pounds of dry trimmed cannabis flower per acre per year, which represents approximately 128,000 pounds, or 64 tons, of dry trimmed cannabis flower per year in total.

Notably, Sugarmade also benefits from the acquisition in terms of team capital, as Lemon Glow executive team members will stay on and become the core management team at the cannabis cultivation site, granting the operation over 30 years of cannabis cultivation experience.

“The Lemon Glow team are tremendous additions to the Sugarmade team,” Jimmy Chan, CEO of Sugarmade, commented in announcing the definitive agreement. “They have vast experience and established skills, as well as intricate knowledge of the property and its local grow context. That’s an enormous added value proposition in this deal. We look forward to bringing them on board, ramping up operations at the property, and taking key steps toward delivering on the promise of Sugarmade’s farm-to-door vision.”

Market Opportunity

The California cannabis industry has continued to record tremendous growth since voters approved a measure to legalize recreational use of the plant in 2016. According to data from MJBizDaily, California’s legal market hit $4.4 billion in sales in 2020, up from $2.8 billion in 2019 and $1.4 billion in 2018.

Those figures highlight California’s status as the largest legal cannabis market in the world. With roughly 28 million residents over the age of 21, California is more than twice the combined size of the four states (Arizona, New Jersey, Montana and North Dakota) that legalized cannabis in 2020.

The COVID-19 pandemic was a key driver in the growth of cannabis delivery services throughout the state in 2020. One California cannabis delivery firm reported a 60% increase in new delivery customer sign-ups in the 30 days following the March 13, 2020, declaration of a national emergency. As a result of this boom, tech companies in cannabis ecommerce were able to dramatically increase their market share.
Sugarmade’s continued efforts to develop a farm-to-door vertically integrated cannabis business position it to capitalize on these trends as the California cannabis industry continues to expand moving forward.

Management

Jimmy Chan is the CEO of Sugarmade. He is an experienced business executive instrumental in growing multiple business operations with a strong expertise in international trade and banking, international manufacturing and importation. He is also the founder of CarryOutSupplies.com, a company that revolutionized the custom-printed paper supplies subsector of the quick service restaurant industry, which merged with Sugarmade in 2014.

Sugarmade, Inc. (OTC: SGMD), closed Monday’s trading session at $0.0016, off by 5.8824%, on 52,742,646 volume. The average volume for the last 3 months is 52.743M and the stock's 52-week low/high is $0.000699999/$0.019999999.

Recent News

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

closed Wednesday's trading